

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 10-Q**

---

(Mark One)

**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the Quarterly Period ended March 31, 2016

Or

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the Transition Period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-33626

---

**GENPACT LIMITED**

(Exact name of registrant as specified in its charter)

---

**Bermuda**  
(State or other jurisdiction of  
incorporation or organization)

**98-0533350**  
(I.R.S. Employer  
Identification No.)

**Canon's Court  
22 Victoria Street  
Hamilton HM12  
Bermuda  
(441) 295-2244**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive office)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

|                         |                                                                        |                           |                          |
|-------------------------|------------------------------------------------------------------------|---------------------------|--------------------------|
| Large accelerated filer | <input checked="" type="checkbox"/>                                    | Accelerated filer         | <input type="checkbox"/> |
| Non-accelerated filer   | <input type="checkbox"/> (Do not check if a smaller reporting company) | Smaller reporting company | <input type="checkbox"/> |

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of the registrant's common shares, par value \$0.01 per share, outstanding as of April 29, 2016 was 210,520,443.

---

---

**TABLE OF CONTENTS**

|                   | <u>Item No.</u> |                                                                                                                                                                                                                     | <u>Page No.</u> |
|-------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| <b>PART I</b>     |                 | <b>Financial Statements</b>                                                                                                                                                                                         |                 |
|                   | 1.              | Unaudited Consolidated Financial Statements                                                                                                                                                                         |                 |
|                   |                 | <a href="#">Consolidated Balance Sheets as of December 31, 2015 and March 31, 2016</a>                                                                                                                              | 1               |
|                   |                 | <a href="#">Consolidated Statements of Income for the three months ended March 31, 2015 and 2016</a>                                                                                                                | 2               |
|                   |                 | <a href="#">Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2015 and 2016</a>                                                                                           | 3               |
|                   |                 | <a href="#">Consolidated Statements of Equity for the three months ended March 31, 2015 and Consolidated Statements of Equity and Redeemable Non-controlling Interest for the three months ended March 31, 2016</a> | 4               |
|                   |                 | <a href="#">Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2016</a>                                                                                                            | 6               |
|                   |                 | <a href="#">Notes to the Consolidated Financial Statements</a>                                                                                                                                                      | 7               |
|                   | 2.              | <a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>                                                                                                               | 28              |
|                   | 3.              | <a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>                                                                                                                                          | 38              |
|                   | 4.              | <a href="#">Controls and Procedures</a>                                                                                                                                                                             | 39              |
| <b>PART II</b>    |                 | <b>Other Information</b>                                                                                                                                                                                            |                 |
|                   | 1.              | <a href="#">Legal Proceedings</a>                                                                                                                                                                                   | 39              |
|                   | 1A.             | <a href="#">Risk Factors</a>                                                                                                                                                                                        | 39              |
|                   | 2.              | <a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>                                                                                                                                         | 39              |
|                   | 3.              | <a href="#">Defaults upon Senior Securities</a>                                                                                                                                                                     | 40              |
|                   | 5.              | <a href="#">Other Information</a>                                                                                                                                                                                   | 40              |
|                   | 6.              | <a href="#">Exhibits</a>                                                                                                                                                                                            | 40              |
| <b>SIGNATURES</b> |                 |                                                                                                                                                                                                                     | 41              |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Balance Sheets**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

|                                                                                                                                                                      | Notes | As of December 31,<br>2015 | As of March 31,<br>2016 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------------|-------------------------|
| <b>Assets</b>                                                                                                                                                        |       |                            |                         |
| <i>Current assets</i>                                                                                                                                                |       |                            |                         |
| Cash and cash equivalents                                                                                                                                            | 4     | \$ 450,907                 | \$ 429,795              |
| Accounts receivable, net                                                                                                                                             | 5     | 590,137                    | 605,598                 |
| Prepaid expenses and other current assets                                                                                                                            | 8     | 154,025                    | 198,535                 |
| <b>Total current assets</b>                                                                                                                                          |       | <b>\$ 1,195,069</b>        | <b>\$ 1,233,928</b>     |
| Property, plant and equipment, net                                                                                                                                   | 9     | 175,396                    | 179,699                 |
| Deferred tax assets                                                                                                                                                  | 22    | 99,395                     | 103,906                 |
| Investment in equity affiliates                                                                                                                                      | 23    | 6,677                      | 8,315                   |
| Intangible assets, net                                                                                                                                               | 10    | 98,601                     | 89,648                  |
| Goodwill                                                                                                                                                             | 10    | 1,038,346                  | 1,055,737               |
| Other assets                                                                                                                                                         |       | 180,005                    | 172,331                 |
| <b>Total assets</b>                                                                                                                                                  |       | <b>\$ 2,793,489</b>        | <b>\$ 2,843,564</b>     |
| <b>Liabilities and equity</b>                                                                                                                                        |       |                            |                         |
| <i>Current liabilities</i>                                                                                                                                           |       |                            |                         |
| Short-term borrowings                                                                                                                                                | 11    | \$ 21,500                  | \$ 81,500               |
| Current portion of long-term debt                                                                                                                                    | 12    | 39,134                     | 39,148                  |
| Accounts payable                                                                                                                                                     |       | 10,086                     | 9,222                   |
| Income taxes payable                                                                                                                                                 | 22    | 24,122                     | 33,079                  |
| Accrued expenses and other current liabilities                                                                                                                       | 13    | 499,638                    | 427,420                 |
| <b>Total current liabilities</b>                                                                                                                                     |       | <b>\$ 594,480</b>          | <b>\$ 590,369</b>       |
| Long-term debt, less current portion                                                                                                                                 | 12    | 737,332                    | 727,538                 |
| Deferred tax liabilities                                                                                                                                             | 22    | 2,093                      | 1,977                   |
| Other liabilities                                                                                                                                                    |       | 155,228                    | 170,455                 |
| <b>Total liabilities</b>                                                                                                                                             |       | <b>\$ 1,489,133</b>        | <b>\$ 1,490,339</b>     |
| <b>Redeemable non-controlling interest</b>                                                                                                                           |       | —                          | 3,621                   |
| <b>Shareholders' equity</b>                                                                                                                                          |       |                            |                         |
| Preferred shares, \$0.01 par value, 250,000,000 authorized, none issued                                                                                              |       | —                          | —                       |
| Common shares, \$0.01 par value, 500,000,000 authorized, 211,472,312 and 210,490,107 issued and outstanding as of December 31, 2015 and March 31, 2016, respectively |       | 2,111                      | 2,100                   |
| Additional paid-in capital                                                                                                                                           |       | 1,342,022                  | 1,354,406               |
| Retained earnings                                                                                                                                                    |       | 411,508                    | 437,043                 |
| Accumulated other comprehensive income (loss)                                                                                                                        |       | (451,285)                  | (443,945)               |
| <b>Total equity</b>                                                                                                                                                  |       | <b>\$ 1,304,356</b>        | <b>\$ 1,349,604</b>     |
| Commitments and contingencies                                                                                                                                        | 24    |                            |                         |
| <b>Total liabilities, redeemable non-controlling interest and equity</b>                                                                                             |       | <b>\$ 2,793,489</b>        | <b>\$ 2,843,564</b>     |

See accompanying notes to the Consolidated Financial Statements.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statements of Income**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

|                                                                                                                                          | <u>Notes</u> | <u>Three months ended March 31,</u> |                   |
|------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------------------------|-------------------|
|                                                                                                                                          |              | <u>2015</u>                         | <u>2016</u>       |
| Net revenues                                                                                                                             |              | \$ 587,153                          | \$ 609,703        |
| Cost of revenue                                                                                                                          | 18, 23       | 357,476                             | 372,848           |
| <b>Gross profit</b>                                                                                                                      |              | <b>\$ 229,677</b>                   | <b>\$ 236,855</b> |
| <i>Operating expenses:</i>                                                                                                               |              |                                     |                   |
| Selling, general and administrative expenses                                                                                             | 19, 23       | 148,748                             | 160,149           |
| Amortization of acquired intangible assets                                                                                               | 10           | 7,341                               | 6,145             |
| Other operating (income) expense, net                                                                                                    | 20           | (462)                               | (5,061)           |
| <b>Income from operations</b>                                                                                                            |              | <b>\$ 74,050</b>                    | <b>\$ 75,622</b>  |
| Foreign exchange gains (losses), net                                                                                                     |              | (7,545)                             | (998)             |
| Interest income (expense), net                                                                                                           | 21           | (9,025)                             | (2,838)           |
| Other income (expense), net                                                                                                              |              | 458                                 | 878               |
| <b>Income before equity-method investment activity, net and income tax expense</b>                                                       |              | <b>\$ 57,938</b>                    | <b>\$ 72,664</b>  |
| Gain (loss) on equity-method investment activity, net                                                                                    |              | (2,223)                             | (2,145)           |
| <b>Income before income tax expense</b>                                                                                                  |              | <b>\$ 55,715</b>                    | <b>\$ 70,519</b>  |
| Income tax expense                                                                                                                       | 22           | 11,062                              | 12,243            |
| <b>Net income</b>                                                                                                                        |              | <b>\$ 44,653</b>                    | <b>\$ 58,276</b>  |
| Net loss (income) attributable to non-controlling interest                                                                               |              | —                                   | 289               |
| <b>Net income attributable to Genpact Limited shareholders</b>                                                                           |              | <b>\$ 44,653</b>                    | <b>\$ 58,565</b>  |
| Net income available to Genpact Limited common shareholders                                                                              | 17           | \$ 44,653                           | \$ 58,565         |
| Earnings per common share attributable to Genpact Limited common shareholders                                                            | 17           |                                     |                   |
| Basic                                                                                                                                    |              | \$ 0.20                             | \$ 0.28           |
| Diluted                                                                                                                                  |              | \$ 0.20                             | \$ 0.27           |
| Weighted average number of common shares used in computing earnings per common share attributable to Genpact Limited common shareholders |              |                                     |                   |
| Basic                                                                                                                                    |              | 219,892,695                         | 210,780,165       |
| Diluted                                                                                                                                  |              | 222,347,101                         | 213,892,964       |

See accompanying notes to the Consolidated Financial Statements.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statements of Comprehensive Income (Loss)**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

|                                                                           | <b>Three months ended March 31,</b>     |                                                    |                                             |                                                 |
|---------------------------------------------------------------------------|-----------------------------------------|----------------------------------------------------|---------------------------------------------|-------------------------------------------------|
|                                                                           | <b>2015</b>                             |                                                    | <b>2016</b>                                 |                                                 |
|                                                                           | <u>Genpact Limited<br/>Shareholders</u> | <u>Redeemable<br/>Non-controlling<br/>interest</u> | <u>Genpact<br/>Limited<br/>Shareholders</u> | <u>Redeemable Non-<br/>controlling interest</u> |
| Net Income (loss)                                                         | \$ 44,653                               | \$ —                                               | \$ 58,565                                   | \$ (289)                                        |
| Other comprehensive income:                                               |                                         |                                                    |                                             |                                                 |
| Currency translation adjustments                                          | (11,179)                                | —                                                  | 5,217                                       | —                                               |
| Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7) | 21,833                                  | —                                                  | 1,970                                       | —                                               |
| Retirement benefits, net of taxes                                         | 286                                     | —                                                  | 153                                         | —                                               |
| Other comprehensive income (loss)                                         | \$ 10,940                               | \$ —                                               | \$ 7,340                                    | \$ —                                            |
| Comprehensive income (loss)                                               | <u>\$ 55,593</u>                        | <u>\$ —</u>                                        | <u>\$ 65,905</u>                            | <u>\$ (289)</u>                                 |

See accompanying notes to the Consolidated Financial Statements.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statements of Equity**  
**(Unaudited)**  
**(In thousands, except share count)**

|                                                                               | Common shares      |                 | Additional Paid-in<br>Capital | Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive<br>Income (Loss) | Total<br>Equity    |
|-------------------------------------------------------------------------------|--------------------|-----------------|-------------------------------|----------------------|--------------------------------------------------------|--------------------|
|                                                                               | No. of Shares      | Amount          |                               |                      |                                                        |                    |
| <b>Balance as of January 1, 2015</b>                                          | <b>218,684,205</b> | <b>\$ 2,184</b> | <b>\$ 1,296,730</b>           | <b>\$398,706</b>     | <b>\$ (412,484)</b>                                    | <b>\$1,285,136</b> |
| Issuance of common shares on exercise of options (Note 15)                    | 659,257            | 7               | 5,834                         | —                    | —                                                      | 5,841              |
| Issuance of common shares under the employee stock purchase plan<br>(Note 15) | 34,162             | —               | 683                           | —                    | —                                                      | 683                |
| Net settlement on vesting of restricted share units (Note 15)                 | 65,244             | 1               | (79)                          | —                    | —                                                      | (78)               |
| Net settlement on vesting of performance units (Note 15)                      | 845,524            | 8               | (8)                           | —                    | —                                                      | —                  |
| Stock repurchased and retired (Note 16)                                       | (590,713)          | (6)             | —                             | (13,292)             | —                                                      | (13,298)           |
| Expenses related to stock purchase (Note 16)                                  | —                  | —               | —                             | (12)                 | —                                                      | (12)               |
| Stock-based compensation expense (Note 15)                                    | —                  | —               | 4,660                         | —                    | —                                                      | 4,660              |
| Comprehensive income:                                                         |                    |                 |                               |                      |                                                        |                    |
| Net income                                                                    | —                  | —               | —                             | 44,653               | —                                                      | 44,653             |
| Other comprehensive income                                                    | —                  | —               | —                             | —                    | 10,940                                                 | 10,940             |
| <b>Balance as of March 31, 2015</b>                                           | <b>219,697,679</b> | <b>\$ 2,194</b> | <b>\$ 1,307,820</b>           | <b>\$430,055</b>     | <b>\$ (401,544)</b>                                    | <b>\$1,338,525</b> |

See accompanying notes to the Consolidated Financial Statements.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statements of Equity and Redeemable Non-controlling Interest**  
**(Unaudited)**  
**(In thousands, except share count)**

|                                                                            | Common shares             |                        | Additional Paid-in Capital | Retained Earnings        | Accumulated Other Comprehensive Income (Loss) | Total Equity              | Redeemable non-controlling interest |
|----------------------------------------------------------------------------|---------------------------|------------------------|----------------------------|--------------------------|-----------------------------------------------|---------------------------|-------------------------------------|
|                                                                            | No. of Shares             | Amount                 |                            |                          |                                               |                           |                                     |
| <b>Balance as of January 1, 2016</b>                                       | <b>211,472,312</b>        | <b>\$ 2,111</b>        | <b>\$ 1,342,022</b>        | <b>\$ 411,508</b>        | <b>\$ (451,285)</b>                           | <b>\$1,304,356</b>        | <b>\$ —</b>                         |
| Issuance of common shares on exercise of options (Note 15)                 | 248,316                   | 2                      | 4,210                      | —                        | —                                             | 4,212                     | —                                   |
| Issuance of common shares under the employee stock purchase plan (Note 15) | 30,487                    | —                      | 725                        | —                        | —                                             | 725                       | —                                   |
| Net settlement on vesting of restricted share units (Note 15)              | 95,191                    | 1                      | (50)                       | —                        | —                                             | (49)                      | —                                   |
| Net settlement on vesting of performance units (Note 15)                   | —                         | —                      | —                          | —                        | —                                             | —                         | —                                   |
| Stock repurchased and retired (Note 16)                                    | (1,356,199)               | (14)                   | —                          | (33,003)                 | —                                             | (33,017)                  | —                                   |
| Excess tax benefit on stock-based Compensation                             | —                         | —                      | 2,163                      | —                        | —                                             | 2,163                     | —                                   |
| Expenses related to stock purchase (Note 16)                               | —                         | —                      | —                          | (27)                     | —                                             | (27)                      | —                                   |
| Stock-based compensation expense (Note 15)                                 | —                         | —                      | 5,336                      | —                        | —                                             | 5,336                     | —                                   |
| Acquisition of redeemable non-controlling interest                         | —                         | —                      | —                          | —                        | —                                             | —                         | 3,910                               |
| Comprehensive income:                                                      |                           |                        |                            |                          |                                               |                           |                                     |
| Net income                                                                 | —                         | —                      | —                          | 58,565                   | —                                             | 58,565                    | (289)                               |
| Other comprehensive income                                                 | —                         | —                      | —                          | —                        | 7,340                                         | 7,340                     | —                                   |
| <b>Balance as of March 31, 2016</b>                                        | <b><u>210,490,107</u></b> | <b><u>\$ 2,100</u></b> | <b><u>\$ 1,354,406</u></b> | <b><u>\$ 437,043</u></b> | <b><u>\$ (443,945)</u></b>                    | <b><u>\$1,349,604</u></b> | <b><u>\$ 3,621</u></b>              |

See accompanying notes to the Consolidated Financial Statements.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statements of Cash Flows**  
**(Unaudited)**  
**(In thousands)**

|                                                                                                     | <b>Three months ended March 31,</b> |                    |
|-----------------------------------------------------------------------------------------------------|-------------------------------------|--------------------|
|                                                                                                     | <b>2015</b>                         | <b>2016</b>        |
| <b>Operating activities</b>                                                                         |                                     |                    |
| Net income attributable to Genpact Limited shareholders                                             | \$ 44,653                           | \$ 58,565          |
| Net income (loss) attributable to non-controlling interest                                          | —                                   | (289)              |
| <b>Net income</b>                                                                                   | <b>\$ 44,653</b>                    | <b>\$ 58,276</b>   |
| <i>Adjustments to reconcile net income to net cash provided by (used for) operating activities:</i> |                                     |                    |
| Depreciation and amortization                                                                       | 13,517                              | 13,155             |
| Amortization of debt issuance costs (including loss on extinguishment of debt)                      | 1,840                               | 385                |
| Amortization of acquired intangible assets                                                          | 7,341                               | 6,145              |
| Intangible assets write-down                                                                        | —                                   | 4,943              |
| Reserve for doubtful receivables                                                                    | 872                                 | 3,120              |
| Unrealized loss on revaluation of foreign currency asset/liability                                  | 5,632                               | 354                |
| Equity-method investment activity, net                                                              | 2,223                               | 2,145              |
| Excess tax benefit on stock-based compensation                                                      | —                                   | (2,163)            |
| Stock-based compensation expense                                                                    | 4,660                               | 5,336              |
| Deferred income taxes                                                                               | (2,559)                             | (5,118)            |
| Others, net                                                                                         | (44)                                | 63                 |
| <i>Change in operating assets and liabilities:</i>                                                  |                                     |                    |
| Increase in accounts receivable                                                                     | (13,449)                            | (17,697)           |
| Increase in prepaid expenses, other current assets and other assets                                 | (10,414)                            | (27,123)           |
| Increase (decrease) in accounts payable                                                             | 177                                 | (70)               |
| Decrease in accrued expenses, other current liabilities and other liabilities                       | (42,376)                            | (64,360)           |
| Increase in income taxes payable                                                                    | 12,215                              | 10,823             |
| <b>Net cash provided by (used for) operating activities</b>                                         | <b>\$ 24,288</b>                    | <b>\$ (11,786)</b> |
| <b>Investing activities</b>                                                                         |                                     |                    |
| Purchase of property, plant and equipment                                                           | (13,991)                            | (25,495)           |
| Proceeds from sale of property, plant and equipment                                                 | 576                                 | 132                |
| Investment in equity affiliates                                                                     | (6,701)                             | (3,783)            |
| Payment for business acquisitions, net of cash acquired                                             | (11,678)                            | (2,339)            |
| <b>Net cash used for investing activities</b>                                                       | <b>\$ (31,794)</b>                  | <b>\$ (31,485)</b> |
| <b>Financing activities</b>                                                                         |                                     |                    |
| Repayment of capital lease obligations                                                              | (539)                               | (454)              |
| Payment of debt issuance and refinancing costs                                                      | (1,045)                             | —                  |
| Repayment of long-term debt                                                                         | (1,687)                             | (10,000)           |
| Proceeds from short-term borrowings                                                                 | 1,410,000                           | 60,000             |
| Repayment of short-term borrowings                                                                  | (1,410,000)                         | —                  |
| Proceeds from issuance of common shares under stock-based compensation plans                        | 6,524                               | 4,937              |
| Payment for net settlement of stock-based awards                                                    | (5,603)                             | (49)               |
| Payment of earn-out/deferred consideration                                                          | (126)                               | (965)              |
| Payment for stock purchased and retired                                                             | (13,298)                            | (33,017)           |
| Payment for expenses related to stock purchase                                                      | (12)                                | (27)               |
| Excess tax benefit on stock-based compensation                                                      | —                                   | 2,163              |
| <b>Net cash provided by (used for) financing activities</b>                                         | <b>\$ (15,786)</b>                  | <b>\$ 22,588</b>   |
| Effect of exchange rate changes                                                                     | (4,186)                             | (429)              |
| Net decrease in cash and cash equivalents                                                           | (23,292)                            | (20,683)           |
| Cash and cash equivalents at the beginning of the period                                            | 461,788                             | 450,907            |
| <b>Cash and cash equivalents at the end of the period</b>                                           | <b>\$ 434,310</b>                   | <b>\$ 429,795</b>  |
| <b>Supplementary information</b>                                                                    |                                     |                    |
| Cash paid during the period for interest                                                            | \$ 6,943                            | \$ 3,968           |
| Cash paid during the period for income taxes                                                        | \$ 13,120                           | \$ 23,229          |
| Property, plant and equipment acquired under capital lease obligations                              | \$ 372                              | \$ 283             |

See accompanying notes to the Consolidated Financial Statements.



**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**1. Organization**

The Company is a provider of digitally-powered business process management and services. The architect of the Lean Digital<sup>SM</sup> enterprise, the Company uses its patented Smart Enterprise Processes (SEP<sup>SM</sup>) framework to reimagine its clients' operating models end-to-end, including their middle and back offices. This creates Intelligent Operations<sup>SM</sup> that the Company helps to design, transform, and run. Today, the Company generates impact for a few hundred strategic clients, including approximately one fifth of the Fortune Global 500, and has grown to over 70,000 people in 25 countries.

Prior to December 30, 2004, the business of the Company was conducted through various entities and divisions of GE. On December 30, 2004, in a series of transactions referred to as the "2004 Reorganization," GE transferred such operations to the Company. In August 2007, the Company completed an initial public offering of its common shares. On October 25, 2012, Glory Investments A Limited, formerly known as South Asia Private Investments, an affiliate of Bain Capital Investors, LLC ("Bain Capital"), became the Company's largest shareholder when, together with its affiliated assignees and two additional co-investors, it purchased 67,750,678 common shares of the Company from the Company's initial private equity investors.

**2. Summary of significant accounting policies**

*(a) Basis of preparation and principles of consolidation*

The unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.

The unaudited interim consolidated financial statements reflect all adjustments that management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for interim periods are not necessarily indicative of the results for the full year.

The accompanying unaudited interim consolidated financial statements have been prepared on a consolidated basis and reflect the financial statements of Genpact Limited, a Bermuda company, and all of its subsidiaries that are more than 50% owned and controlled. When the Company does not have a controlling interest in an entity but exerts significant influence on the entity, the Company applies the equity method of accounting. All intercompany transactions and balances are eliminated in consolidation.

Non-controlling interest in subsidiaries that is redeemable outside of the Company's control for cash or other assets is reflected in the mezzanine section between liabilities and equity in the consolidated balance sheets at the redeemable value, which approximates fair value. Redeemable non-controlling interest is adjusted to its fair value at each balance sheet date. Any resulting increases or decreases in the estimated redemption amount are affected by corresponding charges to additional paid-in-capital. The share of non-controlling interest in subsidiary earnings is reflected in net loss (income) attributable to non-controlling interest in the consolidated statements of income.

*(b) Use of estimates*

The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment, intangibles and goodwill, revenue recognition, reserves for doubtful receivables, valuation allowances for deferred tax assets, the valuation of derivative financial instruments, measurements of stock-based compensation, assets and obligations related to employee benefits, and income tax uncertainties and other contingencies. Management believes that the estimates used in the preparation of the consolidated financial statements are reasonable. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Any changes in estimates are adjusted prospectively in the Company's consolidated financial statements.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**2. Summary of significant accounting policies (Continued)***(c) Business combinations, goodwill and other intangible assets*

The Company accounts for its business combinations using the acquisition method of accounting in accordance with ASC 805, Business Combinations, by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value as of each reporting date until the contingency is resolved. Changes in fair value are recognized in earnings. All assets and liabilities of the acquired businesses, including goodwill, are assigned to reporting units. Acquisition-related costs are expensed as incurred under Selling, General and Administrative Expenses.

Goodwill represents the cost of acquired businesses in excess of the fair value of identifiable tangible and intangible net assets purchased. Goodwill is not amortized but is tested for impairment at least on an annual basis on December 31, based on a number of factors, including operating results, business plans and future cash flows. The Company performs an assessment of qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on the assessment of events or circumstances, the Company performs a quantitative assessment of goodwill impairment if it determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on the quantitative impairment analysis, the carrying value of the goodwill of a reporting unit exceeds the fair value of such goodwill, an impairment loss is recognized in an amount equal to the excess. In addition, the Company performs a qualitative assessment of goodwill impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 10 for information and related disclosures.

Intangible assets acquired individually or with a group of other assets or in a business combination are carried at cost less accumulated amortization based on their estimated useful lives as follows:

|                                     |            |
|-------------------------------------|------------|
| Customer-related intangible assets  | 1-14 years |
| Marketing-related intangible assets | 1-10 years |
| Other intangible assets             | 3-9 years  |

Intangible assets are amortized over their estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are consumed or otherwise realized.

In business combinations, where the fair value of identifiable tangible and intangible net assets purchased exceeds the cost of the acquired business, the Company recognizes the resulting gain under "Other operating (income) expense, net" in the Consolidated Statements of Income.

*(d) Financial instruments and concentration of credit risk*

Financial instruments that potentially subject the Company to concentration of credit risk are reflected principally in cash and cash equivalents, derivative financial instruments and accounts receivable. The Company places its cash and cash equivalents and derivative financial instruments with corporations and banks with high investment grade ratings, limits the amount of credit exposure with any one corporation or bank and conducts ongoing evaluations of the creditworthiness of the corporations and banks with which it does business. To reduce its credit risk on accounts receivable, the Company conducts ongoing credit evaluations of its clients. GE accounted for 18% and 18% of receivables as of December 31, 2015 and March 31, 2016, respectively. GE accounted for 19% and 18% of revenues for the three months ended March 31, 2015 and March 31, 2016, respectively.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**2. Summary of significant accounting policies (Continued)**

*(e) Recently adopted accounting pronouncements*

The following recently released accounting standards have been adopted by the Company. Adoption of these standards did not have a material impact on the Company's consolidated results of operations, cash flows, financial position or disclosures:

Effective January 1, 2016, the Company has adopted FASB ASU 2015-01 (Topic 225): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items ("ASU 2015-01"). Such items are defined as transactions or events that are both unusual in nature and infrequent in occurrence, and, currently, are required to be presented separately in the income statement, net of income tax, after income from continuing operations. The changes eliminate the concept of an extraordinary item and, therefore, the presentation of such items will no longer be required. Notwithstanding this change, the Company will still be required to present and disclose a transaction or event that is both unusual in nature and infrequent in occurrence in the notes to the financial statements.

Effective January 1, 2016, the Company has adopted FASB ASU 2015-05 (Topic 350), Customer's Accounting for Fees Paid in a Cloud Computing Arrangement ("ASU 2015-05"), which provides explicit guidance to evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The new guidance clarifies that if a cloud computing arrangement includes a software license, the customer should account for the license consistent with its accounting for other software licenses. If the arrangement does not include a software license, the customer should account for the arrangement as a service contract.

Effective January 1, 2016, the Company has adopted FASB ASU 2015-16 (Topic 805), Business Combinations ("ASU 2015-16"), which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. The guidance requires that the acquirer shall recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined.

Effective January 1, 2016, the Company has adopted FASB ASU 2015-02. In February 2015, the FASB issued ASU No. 2015-02, Amendment to the Consolidation Analysis, which specifies changes to the analysis that an entity must perform to determine whether it should consolidate certain types of legal entities. These changes (i) modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities or voting interest entities, (ii) eliminate the presumption that a general partner should consolidate a limited partnership, (iii) affect the consolidation analysis of reporting entities that are involved with variable interest entities, particularly those that have fee arrangements and related party relationships, and (iv) provide a scope exception from consolidation guidance for reporting entities with interests in legal entities that are required to comply with or operate in accordance with requirements that are similar to those in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.

**3. Business acquisitions**

*(a) Strategic Sourcing Excellence LLC*

On January 8, 2016, the Company acquired 51% of the outstanding equity interest in Strategic Sourcing Excellence LLC ("SSE"), a Delaware limited liability company, for initial cash consideration of \$2,550, subject to adjustment for closing date working capital, transaction expenses and indebtedness. The equity purchase agreement also provides for contingent earn-out consideration of up to \$20,000, payable based on future performance relative to the thresholds specified in the earn-out calculation. Up to \$9,800 of the total potential earn-out consideration, representing the selling equityholders' 49% interest in SSE, is payable only if either the put or call option, each as described below, is exercised.

The equity purchase agreement grants the Company a call option to purchase the remaining 49% equity interest in SSE, which option the Company has the right to exercise between January 1, 2018 and January 31, 2018. If the Company does not exercise its call option during such period, the selling equityholders have the right to exercise a put option between March 1, 2018 and April 30, 2018 to require the Company to purchase their 49% interest in SSE at a price ranging from \$2,450 to \$2,950. This acquisition strengthens the Company's procurement consulting, transformation and strategic sourcing capabilities.

Acquisition-related costs of \$164 have been included in selling, general and administrative expenses as incurred. Through this transaction, the Company has acquired assets with a value of \$327 and assumed liabilities amounting to \$617. The preliminary estimated purchase consideration for the Company's interest in SSE is \$14,490, including the fair value of earn-out consideration and a preliminary adjustment for working capital, transaction expenses and indebtedness. The results of operations of the acquired business, the fair value of the acquired assets and assumed liabilities, and the redeemable non-controlling interest are included in the Company's Consolidated Financial Statements with effect from the date of the acquisition.

In connection with the transaction, the Company recorded \$300 in customer-related intangible assets, with an amortization period of five years. Goodwill arising from the acquisition amounted to \$14,479, which has been allocated to the Company's India reporting unit and is deductible for tax purposes.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**4. Cash and cash equivalents**

Cash and cash equivalents as of December 31, 2015 and March 31, 2016 are comprised of:

|                              | As of December 31,<br>2015 | As of March 31,<br>2016 |
|------------------------------|----------------------------|-------------------------|
| Deposits with banks          | \$ 231,367                 | \$ 170,715              |
| Other cash and bank balances | 219,540                    | 259,080                 |
| <b>Total</b>                 | <b>\$ 450,907</b>          | <b>\$ 429,795</b>       |

**5. Accounts receivable, net of reserve for doubtful receivables**

The following table provides details of the Company's reserve for doubtful receivables:

|                                                 | Year ended December 31,<br>2015 | Three months ended<br>March 31, 2016 |
|-------------------------------------------------|---------------------------------|--------------------------------------|
| Opening Balance as of January 1                 | \$ 15,192                       | \$ 11,530                            |
| Additions charged to cost and expense           | 2,449                           | 3,120                                |
| Deductions/effect of exchange rate fluctuations | (6,111)                         | 27                                   |
| <b>Closing Balance</b>                          | <b>\$ 11,530</b>                | <b>\$ 14,677</b>                     |

Accounts receivable were \$601,667 and \$620,275 and the reserves for doubtful receivables were \$11,530 and \$14,677, resulting in net accounts receivable balances of \$590,137 and \$605,598 as of December 31, 2015 and March 31, 2016, respectively. In addition, accounts receivable due after one year of \$8,348 and \$7,198 as of December 31, 2015 and March 31, 2016, respectively, are included under other assets in the consolidated balance sheets.

Accounts receivable from related parties were \$1,980 and \$1,121 as of December 31, 2015 and March 31, 2016, respectively. There are no reserves for doubtful receivables in respect of amounts due from related parties.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**6. Fair Value Measurements**

The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these items were determined using the following inputs as of December 31, 2015 and March 31, 2016:

|                                              | As of March 31, 2016                            |                                                                         |                                                        |                                                          |
|----------------------------------------------|-------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------|
|                                              | Fair Value Measurements at Reporting Date Using |                                                                         |                                                        |                                                          |
|                                              | Total                                           | Quoted Prices<br>in Active Markets<br>for Identical Assets<br>(Level 1) | Significant Other<br>Observable<br>Inputs<br>(Level 2) | Significant Other<br>Unobservable<br>Inputs<br>(Level 3) |
| <b>Assets</b>                                |                                                 |                                                                         |                                                        |                                                          |
| Derivative instruments (Note a, c)           | \$33,467                                        | \$ —                                                                    | \$ 33,467                                              | \$ —                                                     |
| <b>Total</b>                                 | <b>\$33,467</b>                                 | <b>\$ —</b>                                                             | <b>\$ 33,467</b>                                       | <b>\$ —</b>                                              |
| <b>Liabilities</b>                           |                                                 |                                                                         |                                                        |                                                          |
| Earn-out consideration (Note b, d)           | \$20,853                                        | \$ —                                                                    | \$ —                                                   | \$ 20,853                                                |
| Derivative instruments (Note b, c)           | \$59,110                                        | \$ —                                                                    | \$ 59,110                                              | \$ —                                                     |
| <b>Total</b>                                 | <b>\$79,963</b>                                 | <b>\$ —</b>                                                             | <b>\$ 59,110</b>                                       | <b>\$ 20,853</b>                                         |
| Redeemable non-controlling interest (Note e) | \$ 3,621                                        | \$ —                                                                    | \$ —                                                   | \$ 3,621                                                 |

|                                    | As of December 31, 2015                         |                                                                         |                                                        |                                                          |
|------------------------------------|-------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------|
|                                    | Fair Value Measurements at Reporting Date Using |                                                                         |                                                        |                                                          |
|                                    | Total                                           | Quoted Prices in<br>Active Markets for<br>Identical Assets<br>(Level 1) | Significant Other<br>Observable<br>Inputs<br>(Level 2) | Significant Other<br>Unobservable<br>Inputs<br>(Level 3) |
| <b>Assets</b>                      |                                                 |                                                                         |                                                        |                                                          |
| Derivative instruments (Note a, c) | \$30,380                                        | \$ —                                                                    | \$ 30,380                                              | \$ —                                                     |
| <b>Total</b>                       | <b>\$30,380</b>                                 | <b>\$ —</b>                                                             | <b>\$ 30,380</b>                                       | <b>\$ —</b>                                              |
| <b>Liabilities</b>                 |                                                 |                                                                         |                                                        |                                                          |
| Earn-out consideration (Note b, d) | \$22,820                                        | \$ —                                                                    | \$ —                                                   | \$ 22,820                                                |
| Derivative instruments (Note b, c) | \$59,620                                        | \$ —                                                                    | \$ 59,620                                              | \$ —                                                     |
| <b>Total</b>                       | <b>\$82,440</b>                                 | <b>\$ —</b>                                                             | <b>\$ 59,620</b>                                       | <b>\$ 22,820</b>                                         |

- (a) Included in prepaid expenses and other current assets and other assets in the consolidated balance sheets.
- (b) Included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheets.
- (c) The Company values its derivative instruments based on market observable inputs, including both forward and spot prices for the relevant currencies and interest rate indices for relevant interest rates. The quotes are taken from an independent market database.
- (d) The fair value of earn-out consideration, calculated as the present value of expected future payments to be made to the sellers of the acquired businesses, was derived by estimating the future financial performance of the acquired businesses using the earn-out formula and performance targets specified in each purchase agreement and adjusting the result to reflect the Company's estimate of the likelihood of achievement of such targets. Given the significance of the unobservable inputs, the valuations are classified in level 3 of the fair value hierarchy.
- (e) The Company's estimate of the fair value of redeemable non-controlling interest as of March 31, 2016 is based on unobservable inputs considering the assumptions that market participants would make in pricing the obligation. Given the significance of the unobservable inputs, the valuation was classified in level 3 of the fair value hierarchy. Refer to Note 3—Business Acquisitions.

The following table provides a roll-forward of the fair value of the contingent consideration categorized as level 3 for the three months ended March 31, 2015 and 2016:

|                                                                | Three months ended<br>March 31, |                 |
|----------------------------------------------------------------|---------------------------------|-----------------|
|                                                                | 2015                            | 2016            |
| <b>Opening Balance</b>                                         | <b>\$33,990</b>                 | <b>\$22,820</b> |
| Earn-out consideration payable in connection with acquisitions | —                               | 8,120           |
| Payments made on earn-out consideration                        | (126)                           | (965)           |
| Change in fair value and others                                | (449)                           | (9,122)         |
| <b>Ending balance</b>                                          | <b>\$33,415</b>                 | <b>\$20,853</b> |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**7. Derivative financial instruments**

The Company is exposed to the risk of rate fluctuations on foreign currency assets and liabilities and on foreign currency denominated forecasted cash flows along with exposure to interest rate fluctuation risk on its indebtedness. The Company has established risk management policies, including the use of derivative financial instruments, to hedge foreign currency assets and liabilities, foreign currency denominated forecasted cash flows and interest rate risk. These derivative financial instruments are largely deliverable and non-deliverable forward foreign exchange contracts and interest rate swaps. The Company enters into these contracts with counterparties that are banks or other financial institutions, and the Company considers the risk of non-performance by such counterparties not to be material. The forward foreign exchange contracts and interest rate swaps mature between 0 and 57 months and the forecasted transactions are expected to occur during the same period.

The following table presents the aggregate notional principal amounts of outstanding derivative financial instruments together with the related balance sheet exposure:

|                                                           | Notional principal amounts<br>(note a) |                         | Balance sheet exposure asset<br>(liability) (note b) |                         |
|-----------------------------------------------------------|----------------------------------------|-------------------------|------------------------------------------------------|-------------------------|
|                                                           | As of December 31,<br>2015             | As of March 31,<br>2016 | As of December 31,<br>2015                           | As of March 31,<br>2016 |
| <b>Foreign exchange forward contracts denominated in:</b> |                                        |                         |                                                      |                         |
| United States Dollars (sell) Indian Rupees (buy)          | \$ 1,139,400                           | \$ 1,122,400            | \$ (48,197)                                          | \$ (31,954)             |
| United States Dollars (sell) Mexican Peso (buy)           | 8,520                                  | 6,570                   | (1,163)                                              | (824)                   |
| United States Dollars (sell) Philippines Peso (buy)       | 58,500                                 | 53,075                  | (1,387)                                              | 224                     |
| Euro (sell) United States Dollars (buy)                   | 146,719                                | 140,385                 | 9,109                                                | 3,787                   |
| Euro (sell) Romanian Leu (buy)                            | 39,027                                 | 31,516                  | 567                                                  | 1,036                   |
| Japanese Yen (sell) Chinese Renminbi (buy)                | 62,740                                 | 61,317                  | (1,379)                                              | (4,765)                 |
| Pound Sterling (sell) United States Dollars (buy)         | 118,438                                | 105,771                 | 7,496                                                | 9,178                   |
| Australian Dollars (sell) United States Dollars (buy)     | 106,544                                | 99,000                  | 5,714                                                | (399)                   |
| Interest rate swaps (floating to fixed)                   | —                                      | 200,000                 | —                                                    | (1,926)                 |
|                                                           |                                        |                         | <u>(29,240)</u>                                      | <u>(25,643)</u>         |

- (a) Notional amounts are key elements of derivative financial instrument agreements but do not represent the amount exchanged by counterparties and do not measure the Company's exposure to credit or market risks. However, the amounts exchanged are based on the notional amounts and other provisions of the underlying derivative financial instrument agreements.
- (b) Balance sheet exposure is denominated in U.S. dollars and denotes the mark-to-market impact of the derivative financial instruments on the reporting date.

FASB guidance on Derivatives and Hedging requires companies to recognize all derivative instruments as either assets or liabilities at fair value in the Balance Sheet. In accordance with the FASB guidance on Derivatives and Hedging, the Company designates foreign exchange forward contracts and interest rate swaps as cash flow hedges. Foreign exchange forward contracts are entered into to cover future variability in exchange rates that affect the Company's forecasted revenues and its purchases of services, and interest rate swaps are entered into to cover interest rate fluctuation risk. In addition to this program, the Company uses derivative instruments that are not accounted for as hedges under the FASB guidance in order to hedge foreign exchange risks related to balance sheet items, such as receivables and intercompany borrowings, denominated in currencies other than the Company's underlying functional currency.

The fair value of the Company's derivative instruments and their location in the Company's financial statements are summarized in the table below:

|                                                | Cash flow hedges           |                         | Non-designated             |                         |
|------------------------------------------------|----------------------------|-------------------------|----------------------------|-------------------------|
|                                                | As of December 31,<br>2015 | As of March 31,<br>2016 | As of December 31,<br>2015 | As of March 31,<br>2016 |
| <b>Assets</b>                                  |                            |                         |                            |                         |
| Prepaid expenses and other current assets      | \$ 17,400                  | \$ 18,164               | \$ 884                     | \$ 1,872                |
| Other assets                                   | \$ 12,096                  | \$ 13,431               | \$ —                       | \$ —                    |
| <b>Liabilities</b>                             |                            |                         |                            |                         |
| Accrued expenses and other current liabilities | \$ 34,576                  | \$ 28,510               | \$ 34                      | \$ 208                  |
| Other liabilities                              | \$ 25,010                  | \$ 30,392               | \$ —                       | \$ —                    |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**7. Derivative financial instruments (Continued)***Cash flow hedges*

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain (loss) on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction is recognized in the consolidated statements of income. Gains (losses) on the derivatives, representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, are recognized in earnings as incurred.

In connection with cash flow hedges, the gains (losses) recorded as a component of other comprehensive income (loss), or OCI, and the related tax effects are summarized below:

|                                                                                               | Three months ended March 31, |                                   |                          |                          |                                   |                          |
|-----------------------------------------------------------------------------------------------|------------------------------|-----------------------------------|--------------------------|--------------------------|-----------------------------------|--------------------------|
|                                                                                               | 2015                         |                                   |                          | 2016                     |                                   |                          |
|                                                                                               | Before-<br>Tax<br>amount     | Tax<br>(Expense)<br>or<br>Benefit | Net of<br>tax<br>Amount  | Before-<br>Tax<br>amount | Tax<br>(Expense)<br>or<br>Benefit | Net of<br>tax<br>Amount  |
| Opening balance as of January 1                                                               | \$(66,786)                   | \$ 23,646                         | \$(43,140)               | \$(30,090)               | \$ 9,830                          | \$(20,260)               |
| Net gains (losses) reclassified into statement of income on completion of hedged transactions | (9,254)                      | 3,251                             | (6,003)                  | (2,902)                  | 702                               | (2,200)                  |
| Changes in fair value of effective portion of outstanding derivatives, net                    | 24,564                       | (8,734)                           | 15,830                   | (79)                     | (151)                             | (230)                    |
| Gain (loss) on cash flow hedging derivatives, net                                             | 33,818                       | (11,985)                          | 21,833                   | 2,823                    | (853)                             | 1,970                    |
| Closing balance as of March 31                                                                | <u><b>\$(32,968)</b></u>     | <u><b>\$ 11,661</b></u>           | <u><b>\$(21,307)</b></u> | <u><b>\$(27,267)</b></u> | <u><b>\$ 8,977</b></u>            | <u><b>\$(18,290)</b></u> |



**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**7. Derivative financial instruments (Continued)**

The gains or losses recognized in other comprehensive income (loss) and their effects on financial performance are summarized below:

| <u>Derivatives in Cash Flow Hedging Relationships</u> | Amount of Gain (Loss) recognized in OCI on Derivatives (Effective Portion) |                | Location of Gain (Loss) reclassified from OCI into Statement of Income (Effective Portion) | Amount of Gain (Loss) reclassified from OCI into Statement of Income (Effective Portion) |                   | Location of Gain (Loss) recognized in Income on Derivatives (Ineffective Portion and Amount excluded from Effectiveness Testing) | Amount of Gain (Loss) recognized in income on Derivatives (Ineffective Portion and Amount excluded from Effectiveness Testing) |             |
|-------------------------------------------------------|----------------------------------------------------------------------------|----------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------|
|                                                       | Three months ended March 31,                                               |                |                                                                                            | Three months ended March 31,                                                             |                   |                                                                                                                                  | Three months ended March 31,                                                                                                   |             |
|                                                       | 2015                                                                       | 2016           |                                                                                            | 2015                                                                                     | 2016              |                                                                                                                                  | 2015                                                                                                                           | 2016        |
| Forward foreign exchange contracts                    | \$ 24,564                                                                  | \$ 1,847       | Revenue                                                                                    | \$ 2,495                                                                                 | \$ 3,871          | Foreign exchange (gains) losses, net                                                                                             | \$ —                                                                                                                           | \$ —        |
| Interest rate swaps                                   | —                                                                          | (1,926)        | Cost of revenue                                                                            | (9,427)                                                                                  | (5,312)           |                                                                                                                                  |                                                                                                                                |             |
|                                                       |                                                                            |                | Selling, general and administrative expenses                                               | (2,322)                                                                                  | (1,461)           |                                                                                                                                  |                                                                                                                                |             |
|                                                       | <u>\$ 24,564</u>                                                           | <u>\$ (79)</u> |                                                                                            | <u>\$ (9,254)</u>                                                                        | <u>\$ (2,902)</u> |                                                                                                                                  | <u>\$ —</u>                                                                                                                    | <u>\$ —</u> |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**7. Derivative financial instruments (Continued)***Non-designated Hedges*

| <u>Derivatives not designated as hedging instruments</u> | <u>Location of (Gain) Loss<br/>recognized in Statement of<br/>Income on Derivatives</u> | <u>Amount of (Gain) Loss<br/>recognized in Statement of<br/>Income on Derivatives</u> |                   |
|----------------------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------|
|                                                          |                                                                                         | <u>Three months ended March 31,</u>                                                   |                   |
|                                                          |                                                                                         | <u>2015</u>                                                                           | <u>2016</u>       |
| Forward foreign exchange contracts (Note a)              | Foreign exchange (gains) losses, net                                                    | \$ (2,244)                                                                            | \$ (1,134)        |
|                                                          |                                                                                         | <u>\$ (2,244)</u>                                                                     | <u>\$ (1,134)</u> |

- (a) These forward foreign exchange contracts were entered into to hedge fluctuations in foreign exchange rates for recognized balance sheet items such as receivables and intercompany borrowings, and were not originally designated as hedges under FASB guidance on derivatives and hedging. Realized (gains) losses and changes in the fair value of these derivatives are recorded in foreign exchange (gains) losses, net in the consolidated statements of income.

**8. Prepaid expenses and other current assets**

Prepaid expenses and other current assets consist of the following:

|                                     | <u>As of December 31,<br/>2015</u> | <u>As of March 31,<br/>2016</u> |
|-------------------------------------|------------------------------------|---------------------------------|
| Advance income and non-income taxes | \$ 52,953                          | \$ 97,466                       |
| Deferred transition costs           | 36,620                             | 37,594                          |
| Derivative instruments              | 18,284                             | 20,036                          |
| Prepaid expenses                    | 12,565                             | 13,231                          |
| Customer acquisition cost           | 6,687                              | 8,282                           |
| Employee advances                   | 3,878                              | 4,787                           |
| Deposits                            | 1,820                              | 1,745                           |
| Advances to suppliers               | 8,028                              | 7,309                           |
| Others                              | 13,190                             | 8,085                           |
|                                     | <u>\$ 154,025</u>                  | <u>\$ 198,535</u>               |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**9. Property, plant and equipment, net**

Property, plant and equipment, net consist of the following:

|                                                 | <u>As of December 31,</u><br><u>2015</u> | <u>As of March 31,</u><br><u>2016</u> |
|-------------------------------------------------|------------------------------------------|---------------------------------------|
| Property, plant and equipment, gross            | \$ 556,518                               | \$ 569,559                            |
| Less: Accumulated depreciation and amortization | (381,122)                                | (389,860)                             |
| Property, plant and equipment, net              | <u>\$ 175,396</u>                        | <u>\$ 179,699</u>                     |

Depreciation expense on property, plant and equipment for the three months ended March 31, 2015 and 2016 was \$11,717 and \$11,104, respectively. Computer software amortization for the three months ended March 31, 2015 and 2016 amounted to \$2,362 and \$2,345, respectively.

The depreciation and amortization expenses set forth above include the effect of the reclassification of foreign exchange (gains) losses related to the effective portion of foreign currency derivative contracts, amounting to \$562 and \$294 for the three months ended March 31, 2015 and 2016, respectively.

**10. Goodwill and intangible assets**

The following table presents the changes in goodwill for the year ended December 31, 2015 and three months ended March 31, 2016:

|                                                                 | <u>As of December 31,</u><br><u>2015</u> | <u>As of March 31,</u><br><u>2016</u> |
|-----------------------------------------------------------------|------------------------------------------|---------------------------------------|
| Opening balance                                                 | \$ 1,057,214                             | \$ 1,038,346                          |
| Goodwill relating to acquisitions consummated during the period | 7,674                                    | 14,479                                |
| Impact of measurement period adjustments                        | (135)                                    | —                                     |
| Effect of exchange rate fluctuations                            | (26,407)                                 | 2,912                                 |
| Closing balance                                                 | <u>\$ 1,038,346</u>                      | <u>\$ 1,055,737</u>                   |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**10. Goodwill and intangible assets (Continued)**

The total amount of goodwill deductible for tax purposes is \$36,390 and \$38,070 as of December 31, 2015 and March 31, 2016, respectively.

The Company's intangible assets acquired either individually or with a group of other assets or in a business combination are as follows:

|                                     | As of December 31, 2015 |                                         |          | As of March 31, 2016  |                                         |          |
|-------------------------------------|-------------------------|-----------------------------------------|----------|-----------------------|-----------------------------------------|----------|
|                                     | Gross carrying amount   | Accumulated amortization and impairment | Net      | Gross carrying amount | Accumulated amortization and impairment | Net      |
| Customer-related intangible assets  | \$ 319,035              | \$ 247,463                              | \$71,572 | \$320,177             | \$ 252,899                              | \$67,278 |
| Marketing-related intangible assets | 42,749                  | 27,021                                  | 15,728   | 42,697                | 27,763                                  | 14,934   |
| Other intangible assets             | 29,729                  | 18,427                                  | 11,301   | 31,137                | 23,701                                  | 7,436    |
|                                     | \$ 391,513              | \$ 292,911                              | \$98,601 | \$394,011             | \$ 304,363                              | \$89,648 |

Amortization expenses for intangible assets disclosed in the consolidated statements of income under amortization of acquired intangible assets for the three months ended March 31, 2015 and 2016 were \$7,341 and \$6,145, respectively.

During the three months ended March 31, 2016, the Company tested an intangible software asset for recoverability as a result of a downward revision to the forecasted cash flows to be generated by the intangible asset. Based on the results of such testing, the Company determined that the carrying value of the intangible asset exceeded the estimated undiscounted cash flows by \$4,943 and recorded an additional charge to further reduce the carrying value by this amount. The Company used a combination of the income and cost approaches to determine the fair value of the intangible asset for the purpose of calculating the charge. This charge has been recorded in other operating (income) expenses, net in the consolidated statement of income.

**11. Short-term borrowings**

The Company has the following borrowing facilities:

- (a) Fund-based and non-fund-based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2015 and March 31, 2016, the limits available were \$15,781 and \$15,502, respectively, of which \$10,301 and \$10,630 was utilized, constituting non-funded drawdown.
- (b) A fund-based and non-fund based revolving credit facility of \$350,000, which the company obtained in June 2015 as described in note 12. This facility replaces the Company's \$250,000 facility initially entered into in August 2012 and subsequently amended in June 2013. As of December 31, 2015 and March 31, 2016, a total of \$22,947 and \$82,947, respectively, was utilized, of which \$21,500 and \$81,500, respectively, constituted funded drawdown and \$1,447 and \$1,447, respectively, constituted non-funded drawdown. The revolving facility expires in June 2020. The funded drawdown amount bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum as of December 31, 2015. As of March 31, 2016, the revolving facility bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum. The unutilized amount on the revolving facility bore a commitment fee of 0.25% as of December 31, 2015 and March 31, 2016. The credit agreement contains certain customary covenants, including a maximum leverage covenant and a minimum interest coverage ratio. For the three months ended March 31, 2016, the Company was in compliance with the financial covenants.
- (c) On January 27, 2015 and March 23, 2015, the Company obtained short-term loans of \$672,500 and \$737,500, respectively, from Morgan Stanley Senior Funding, Inc. in connection with certain internal reorganization transactions. These loans bore interest at a rate of 2.00% per annum and were fully repaid on January 30, 2015 and March 26, 2015, respectively. The Company recorded \$1,045 in debt issuance expenses and \$235 in interest with respect to the amounts borrowed under the short-term loans.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**12. Long-term debt**

In August 2012, the Company obtained credit facilities aggregating \$925,000 from a consortium of financial institutions.

In June 2013, the Company amended this credit facility to reduce interest payments thereunder. As of the amendment date, the gross outstanding term loan amounted to \$671,625. The amendment did not result in a substantial modification of \$553,589 of the outstanding term loan under the previous credit facility. As a result of the amendment, the Company extinguished \$118,036 of the outstanding term loan under the previous facility and obtained additional funding amounting to \$121,410, increasing the total term loan outstanding to \$675,000. The Company expensed \$3,103, representing partial acceleration of the amortization of the existing unamortized debt issuance costs and an additional fee paid to the lenders in respect of the extinguished amount. The overall borrowing capacity under the revolving facility did not change. The amendment of the revolving facility resulted in accelerated amortization of \$54 relating to the existing unamortized debt issuance cost. The remaining unamortized costs and an additional third party fee paid in connection with the amendment were to be amortized over the duration of the term loan and revolving facility, which by their terms were to expire on August 30, 2019 and August 30, 2017, respectively.

In June 2015, the Company refinanced its 2012 facility through a new credit facility, comprised of an \$800,000 term loan and a \$350,000 revolving credit facility. Borrowings under the new facility bear interest at a rate equal to, at the election of the Company, either LIBOR plus an applicable margin equal to 1.50% per annum or a base rate plus an applicable margin equal to 0.50% per annum, in each case subject to adjustment based on the Company's debt ratings provided by Standard & Poor's Rating Services and Moody's Investors Service, Inc. Based on the Company's election and current credit rating, the applicable interest rate is equal to LIBOR plus 1.50% per annum. As a result of the June 2015 refinancing, the gross outstanding term loan under the previous facility, which amounted to \$663,188 as of June 30, 2015, was extinguished, and the Company expensed \$10,050, representing accelerated amortization of the existing unamortized debt issuance costs related to the prior facility. Additionally, the refinancing of the revolving facility resulted in the accelerated amortization of \$65 relating to the existing unamortized debt issuance cost. The remaining unamortized costs for the revolving facility, together with the fees paid to the Company's lenders and third parties in connection with the new term loan and revolving facility, will be amortized over the term of the refinanced facility, which ends on June 30, 2020.

As of December 31, 2015 and March 31, 2016, the amount outstanding under the term loan, net of debt amortization expense of \$3,534 and \$3,314, was \$776,466 and \$766,686, respectively. As of December 31, 2015 and March 31, 2016, the term loan bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum. Indebtedness under the refinanced facility is unsecured. The amount outstanding on the term loan as of March 31, 2016 will be repaid through quarterly payments of \$10,000, and the balance will be repaid upon the maturity of the term loan on June 30, 2020.

The maturity profile of the term loan, net of debt amortization expense, is as follows:

| <b>Year ended</b> | <b>Amount</b>    |
|-------------------|------------------|
| 2016              | \$ 29,353        |
| 2017              | 39,181           |
| 2018              | 39,226           |
| 2019              | 39,272           |
| 2020              | 619,654          |
| Total             | <u>\$766,686</u> |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**13. Accrued expenses and other current liabilities**

Accrued expenses and other current liabilities consist of the following:

|                             | <u>As of December 31,</u><br><u>2015</u> | <u>As of March 31,</u><br><u>2016</u> |
|-----------------------------|------------------------------------------|---------------------------------------|
| Accrued expenses            | \$ 161,672                               | \$ 147,140                            |
| Accrued employee cost       | 158,054                                  | 96,541                                |
| Deferred transition revenue | 44,974                                   | 45,157                                |
| Statutory liabilities       | 32,149                                   | 45,056                                |
| Retirement benefits         | 17,930                                   | 22,665                                |
| Derivative instruments      | 34,610                                   | 28,718                                |
| Advance from customers      | 19,815                                   | 23,649                                |
| Earn-out consideration      | 16,896                                   | 4,742                                 |
| Other liabilities           | 12,210                                   | 12,468                                |
| Capital lease obligations   | 1,328                                    | 1,284                                 |
|                             | <u>\$ 499,638</u>                        | <u>\$ 427,420</u>                     |

**14. Employee benefit plans**

The Company has employee benefit plans in the form of certain statutory and other schemes covering its employees.

**Defined benefit plans**

In accordance with Indian law, the Company provides a defined benefit retirement plan covering substantially all of its Indian employees. In accordance with Mexican law, the Company provides termination benefits to all of its Mexican employees. In addition, certain of the Company's subsidiaries in the Philippines and Japan sponsor defined benefit retirement programs.

Net defined benefit plan costs for the three months ended March 31, 2015 and 2016 include the following components:

|                                | <u>Three months ended March 31,</u> |                 |
|--------------------------------|-------------------------------------|-----------------|
|                                | <u>2015</u>                         | <u>2016</u>     |
| Service costs                  | \$ 1,384                            | \$ 1,403        |
| Interest costs                 | 678                                 | 698             |
| Amortization of actuarial loss | 85                                  | 56              |
| Expected return on plan assets | (549)                               | (486)           |
| Net defined benefit plan costs | <u>\$ 1,598</u>                     | <u>\$ 1,671</u> |

**Defined contribution plans**

During the three months ended March 31, 2015 and 2016, the Company contributed the following amounts to defined contribution plans in various jurisdictions:

|               | <u>Three months ended March 31,</u> |                  |
|---------------|-------------------------------------|------------------|
|               | <u>2015</u>                         | <u>2016</u>      |
| India         | \$ 3,909                            | \$ 4,303         |
| U.S.          | 2,628                               | 3,532            |
| U.K.          | 1,040                               | 1,652            |
| China         | 3,516                               | 3,753            |
| Other regions | 1,106                               | 1,265            |
| <b>Total</b>  | <u>\$ 12,199</u>                    | <u>\$ 14,505</u> |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**15. Stock-based compensation**

The Company has issued options under the Genpact Global Holdings 2005 Plan (the “2005 Plan”), Genpact Global Holdings 2006 Plan (the “2006 Plan”), Genpact Global Holdings 2007 Plan (the “2007 Plan”) and Genpact Limited 2007 Omnibus Incentive Compensation Plan (the “2007 Omnibus Plan”) to eligible persons, including employees, directors and certain other persons associated with the Company.

With respect to options granted under the 2005, 2006 and 2007 Plans before the date of adoption of the 2007 Omnibus Plan, if an award granted under any such plan is forfeited or otherwise expires, terminates, or is cancelled without the delivery of shares, then the shares covered by the forfeited, expired, terminated, or cancelled award will be added to the number of shares otherwise available for grant under the respective plans.

Beginning on July 13, 2007, the date of adoption of the 2007 Omnibus Plan, shares underlying options forfeited, expired, terminated, or cancelled under any of the plans are added to the number of shares otherwise available for grant under the 2007 Omnibus Plan. The 2007 Omnibus Plan was amended and restated on April 11, 2012 to increase the number of common shares authorized for issuance by 5,593,200 shares to 15,000,000 shares.

During the year ended December 31, 2012, the number of common shares authorized for issuance under the 2007 Omnibus Plan and the 2005 Plan was increased by 8,858,823 and 495,915 shares, respectively, as a result of an adjustment to outstanding unvested share awards.

Stock-based compensation costs relating to the foregoing plans during the three months ended March 31, 2015 and 2016 were \$4,579 and \$5,250, respectively. These costs have been allocated to cost of revenue and selling, general, and administrative expenses.

**Stock options**

All options granted under the 2007 Omnibus Plan or any prior plans are exercisable into common shares of the Company, have a contractual period of ten years and vest over four to five years unless specified otherwise in the applicable award agreement. The Company recognizes compensation cost over the vesting period of the option. Compensation cost is determined on the date of grant by estimating the fair value of an option using the Black-Scholes option-pricing model.

The following table shows the significant assumptions used in connection with the determination of the fair value of options granted in the three months ended March 31, 2015. No options were granted in the three months ended March 31, 2016.

|                            | <u>Three months ended</u><br><u>March 31, 2015</u> |
|----------------------------|----------------------------------------------------|
| Dividend yield             | —                                                  |
| Expected life (in months)  | 84                                                 |
| Risk free rate of interest | 1.99%                                              |
| Volatility                 | 34.97%                                             |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**15. Stock-based compensation (Continued)**

A summary of stock option activity during the three months ended March 31, 2016 is set out below:

|                                                                      | Three months ended March 31, 2016 |                                    |                                                        | Aggregate<br>intrinsic<br>value |
|----------------------------------------------------------------------|-----------------------------------|------------------------------------|--------------------------------------------------------|---------------------------------|
|                                                                      | Shares arising<br>out of options  | Weighted average<br>exercise price | Weighted average remaining<br>contractual life (years) |                                 |
| Outstanding as of January 1, 2016                                    | 5,986,845                         | \$ 16.99                           | 5.8                                                    | \$ —                            |
| Granted                                                              | —                                 | —                                  | —                                                      | —                               |
| Forfeited                                                            | (25,000)                          | 19.35                              | —                                                      | —                               |
| Expired                                                              | —                                 | —                                  | —                                                      | —                               |
| Exercised                                                            | (248,316)                         | 16.96                              | —                                                      | 2,539                           |
| Outstanding as of March 31, 2016                                     | 5,713,529                         | \$ 16.98                           | 5.5                                                    | \$ 59,157                       |
| Vested as of March 31, 2016 and expected to vest thereafter (Note a) | 5,541,849                         | \$ 16.76                           | 5.5                                                    | \$ 57,790                       |
| Vested and exercisable as of March 31, 2016                          | 3,492,030                         | \$ 15.34                           | 4.3                                                    | \$ 41,382                       |
| Weighted average grant date fair value of grants during the period   | \$ —                              |                                    |                                                        |                                 |

a) Options expected to vest reflect an estimated forfeiture rate.

As of March 31, 2016, the total remaining unrecognized stock-based compensation cost for options expected to vest amounted to \$12,484, which will be recognized over the weighted average remaining requisite vesting period of 2.2 years.

**Restricted Share Units**

The Company has granted restricted share units, or RSUs, under the 2007 Omnibus Plan. Each RSU represents the right to receive one Company common share at a future date. The fair value of each RSU is the market price of one common share of the Company on the date of the grant. RSUs granted to date have graded vesting schedules of three months to four years. The compensation expense is recognized on a straight-line basis over the vesting term. A summary of RSUs granted during the three months ended March 31, 2016 is set out below:

|                                   | Three months ended March 31, 2016 |                                        |
|-----------------------------------|-----------------------------------|----------------------------------------|
|                                   | Number of Restricted Share Units  | Weighted Average Grant Date Fair Value |
| Outstanding as of January 1, 2016 | 157,390                           | \$ 17.67                               |
| Granted                           | —                                 | —                                      |
| Vested (Note a)                   | (5,256)                           | 14.87                                  |
| Forfeited                         | (1,135)                           | 14.18                                  |
| Outstanding as of March 31, 2016  | 150,999                           | \$ 17.80                               |
| Expected to vest (Note b)         | 143,800                           |                                        |



**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**15. Stock-based compensation (Continued)**

- (a) RSUs that vested during the period covered were net settled upon vesting by issuing 3,228 shares (net of minimum statutory tax withholding).  
(b) The number of RSUs expected to vest reflects an estimated forfeiture rate.

92,692 RSUs vested in the year ended December 31, 2014, in respect of which 91,963 shares were issued in January 2016 after withholding shares to the extent of the minimum statutory withholding taxes.

53,546 RSUs vested in the year ended December 31, 2015, shares in respect of which will be issuable on December 31, 2016 after withholding shares to the extent of minimum statutory withholding taxes.

As of March 31, 2016, the total remaining unrecognized stock-based compensation cost related to RSUs amounted to \$1,298, which will be recognized over the weighted average remaining requisite vesting period of 2.0 years.

**Performance Units**

The Company also grants stock awards in the form of performance units, or PUs, under the 2007 Omnibus Plan.

Each PU represents the right to receive one Company common share at a future date based on the Company's performance against specified targets. PUs granted to date have vesting schedules of six months to three years. The fair value of each PU is the market price of one common share of the Company on the date of grant and assumes that performance targets will be achieved. PUs granted under the plan are subject to cliff vesting. The compensation expense for such awards is recognized on a straight-line basis over the vesting terms. During the performance period, the Company's estimate of the number of shares to be issued is adjusted upward or downward based upon the probability of achievement of the performance targets. The ultimate number of shares issued and the related compensation cost recognized is based on a comparison of the final performance metrics to the specified targets.

A summary of PU activity during the three months ended March 31, 2016 is set out below:

|                                                                                          | Three months ended March 31, 2016 |                                              |                                             |
|------------------------------------------------------------------------------------------|-----------------------------------|----------------------------------------------|---------------------------------------------|
|                                                                                          | Number of Performance<br>Units    | Weighted Average<br>Grant Date Fair<br>Value | Maximum<br>Shares<br>Eligible to<br>Receive |
| Outstanding as of January 1, 2016                                                        | 2,499,322                         | \$ 19.95                                     | 2,499,322                                   |
| Granted                                                                                  | —                                 | —                                            | —                                           |
| Vested                                                                                   | —                                 | —                                            | —                                           |
| Forfeited                                                                                | (62,411)                          | 19.56                                        | (62,411)                                    |
| Adjustment upon final determination of level of<br>performance goal achievement (Note a) | 7,274                             | 22.72                                        |                                             |
| Adjustment upon final determination of level of<br>performance goal achievement (Note a) |                                   |                                              | 7,274                                       |
| Outstanding as of March 31, 2016                                                         | 2,444,185                         | \$ 19.96                                     | 2,444,185                                   |
| Expected to vest (Note b)                                                                | 2,211,468                         |                                              |                                             |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**15. Stock-based compensation (Continued)**

- (a) Represents an adjustment made in March 2016 to the number of shares subject to the PUs granted in 2015 upon certification of the level of achievement of the performance targets underlying such awards.
- (b) The number of PUs expected to vest has been adjusted by an estimated forfeiture rate.

As of March 31, 2016, the total remaining unrecognized stock-based compensation costs related to PUs amounted to \$20,591, which will be recognized over the weighted average remaining requisite vesting period of 1.5 years.

**Employee Stock Purchase Plan (ESPP)**

On May 1, 2008, the Company adopted the Genpact Limited U.S. Employee Stock Purchase Plan and the Genpact Limited International Employee Stock Purchase Plan (together, the "ESPP").

The ESPP allows eligible employees to purchase the Company's common shares through payroll deductions at 90% of the closing price of the Company's common shares on the last business day of each purchase interval. The dollar amount of common shares purchased under the ESPP must not exceed 15% of the participating employee's base salary, subject to a cap of \$25 per employee per calendar year. With effect from September 1, 2009, the offering periods commence on the first business day in March, June, September and December of each year and end on the last business day in the subsequent May, August, November and February of each year. 4,200,000 common shares have been reserved for issuance in the aggregate over the term of the ESPP.

During the three months ended March 31, 2015 and 2016, 34,162 and 30,487 common shares, respectively, were issued under ESPP.

The ESPP is considered compensatory under the FASB guidance on Compensation-Stock Compensation.

The compensation expense for the ESPP is recognized in accordance with the FASB guidance on Compensation-Stock Compensation. The compensation expense for the ESPP during the three months ended March 31, 2015 and 2016 was \$81 and \$86, respectively, and has been allocated to cost of revenue and selling, general, and administrative expenses.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**16. Capital stock****Share Repurchases**

In February 2015, the Company's Board of Directors authorized a program to repurchase up to \$250,000 in value of the Company's common shares. The Company's share repurchase program does not obligate it to acquire any specific number of shares. Under the program, shares may be purchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. On February 4, 2016, the Company announced that its Board of Directors approved an additional \$250 million share repurchase program, bringing the total authorization under the Company's existing program to \$500 million. During the three months ended March 31, 2015 and 2016, the Company purchased 590,713 and 1,356,199 of its common shares, respectively at a weighted average price of \$22.51 and \$24.35 per share, respectively, for an aggregate cash amount of \$13,298 and \$33,017, respectively. The purchased shares have been retired.

The Company records repurchases of its common shares on the settlement date of each transaction. Shares purchased and retired are deducted to the extent of their par value from common stock and from retained earnings for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares purchased. For the three months ended March 31, 2015 and 2016, \$12 and \$27, respectively, was deducted from retained earnings in direct costs related to share repurchases.

**17. Earnings per share**

The Company calculates earnings per share in accordance with FASB guidance on Earnings per Share. Basic and diluted earnings per common share give effect to the change in the number of Company common shares. The calculation of basic earnings per common share is determined by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the respective periods. The potentially dilutive shares, consisting of outstanding options on common shares, restricted share units, performance units and common shares to be issued under the employee stock purchase plan, have been included in the computation of diluted net earnings per share and the number of weighted average shares outstanding, except where the result would be anti-dilutive.

The number of stock options outstanding but not included in the computation of diluted earnings per common share because their inclusion would be anti-dilutive is 3,928,000 and 317,081 for the three months ended March 31, 2015 and 2016, respectively.

|                                                                                               | <b>Three months ended March 31,</b> |             |
|-----------------------------------------------------------------------------------------------|-------------------------------------|-------------|
|                                                                                               | <b>2015</b>                         | <b>2016</b> |
| <b>Net income available to Genpact Limited common shareholders</b>                            | \$ 44,653                           | \$ 58,565   |
| Weighted average number of common shares used in computing basic earnings per common share    | 219,892,695                         | 210,780,165 |
| Dilutive effect of stock-based awards                                                         | 2,454,406                           | 3,112,799   |
| Weighted average number of common shares used in computing dilutive earnings per common share | 222,347,101                         | 213,892,964 |
| <b>Earnings per common share attributable to Genpact Limited common shareholders</b>          |                                     |             |
| Basic                                                                                         | \$ 0.20                             | \$ 0.28     |
| Diluted                                                                                       | \$ 0.20                             | \$ 0.27     |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**18. Cost of revenue**

Cost of revenue consists of the following:

|                               | <u>Three months ended March 31,</u> |                   |
|-------------------------------|-------------------------------------|-------------------|
|                               | <u>2015</u>                         | <u>2016</u>       |
| Personnel expenses            | \$ 242,948                          | \$ 254,028        |
| Operational expenses          | 102,797                             | 107,542           |
| Depreciation and amortization | 11,731                              | 11,278            |
|                               | <u>\$ 357,476</u>                   | <u>\$ 372,848</u> |

**19. Selling, general and administrative expenses**

Selling, general and administrative expenses consist of the following:

|                               | <u>Three months ended March 31,</u> |                   |
|-------------------------------|-------------------------------------|-------------------|
|                               | <u>2015</u>                         | <u>2016</u>       |
| Personnel expenses            | \$ 105,838                          | \$ 108,400        |
| Operational expenses          | 40,562                              | 49,578            |
| Depreciation and amortization | 2,348                               | 2,171             |
|                               | <u>\$ 148,748</u>                   | <u>\$ 160,149</u> |

**20. Other operating (income) expense, net**

|                                                                                                                  | <u>Three months ended March 31,</u> |                   |
|------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------|
|                                                                                                                  | <u>2015</u>                         | <u>2016</u>       |
| Other operating (income) expense                                                                                 | \$ (462)                            | \$ (498)          |
| Provision for impairment of intangible assets                                                                    | —                                   | 4,943             |
| Change in fair value of earn out consideration and deferred consideration<br>(relating to business acquisitions) | —                                   | (9,506)           |
| <b>Other operating (income) expense, net</b>                                                                     | <u>\$ (462)</u>                     | <u>\$ (5,061)</u> |

**21. Interest income (expense), net**

|                                       | <u>Three months ended March 31,</u> |                   |
|---------------------------------------|-------------------------------------|-------------------|
|                                       | <u>2015</u>                         | <u>2016</u>       |
| Interest income                       | \$ 1,196                            | \$ 2,364          |
| Interest expense                      | (10,221)                            | (5,202)           |
| <b>Interest income (expense), net</b> | <u>\$ (9,025)</u>                   | <u>\$ (2,838)</u> |

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

## 22. Income taxes

The Company determines its tax provision for interim periods using an estimate of its annual effective tax rate adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if its estimated tax rate changes, the Company makes a cumulative adjustment.

As of December 31, 2015, the Company had unrecognized tax benefits amounting to \$26,357, including an amount of \$24,935, which, if recognized, would impact the effective tax rate.

The following table summarizes activities related to the Company's unrecognized tax benefits for uncertain tax positions from January 1, 2016 to March 31, 2016:

|                                                                                              | 2016                   |
|----------------------------------------------------------------------------------------------|------------------------|
| Opening Balance at January 1                                                                 | \$26,357               |
| Increase related to prior year tax positions, including recorded in acquisition accounting   | 13                     |
| Decrease related to prior year tax positions                                                 | (764)                  |
| Decrease related to prior year tax position due to lapse of applicable statute of limitation | (166)                  |
| Decrease related to settlements with tax authorities                                         | (2,000)                |
| Effect of exchange rate changes                                                              | 119                    |
| <b>Closing Balance at March 31</b>                                                           | <b><u>\$23,559</u></b> |

The Company's unrecognized tax benefits as of March 31, 2016 include an amount of \$22,136, which, if recognized, would impact the effective tax rate. As of December 31, 2015 and March 31, 2016, the Company had accrued approximately \$4,223 and \$3,682, respectively, for interest relating to unrecognized tax benefits. During the year ended December 31, 2015 and the three months ended March 31, 2016, the company recognized approximately \$1,152 and (\$533), respectively, excluding exchange rate differences, in interest on unrecognized tax benefits. As of December 31, 2015 and March 31, 2016, the Company had accrued approximately \$958 and \$958, respectively, for penalties.

## 23. Related party transactions

The Company has entered into related party transactions with its non-consolidating affiliates. The Company has also entered into related party transactions with a significant shareholder and its affiliates.

The Company's related party transactions can be categorized as follows:

### *Revenue from services*

For the three months ended March 31, 2015 and 2016, the Company recognized net revenues of \$99 and \$79, respectively, from a client that is a significant shareholder of the Company.

For the three months ended March 31, 2015 and 2016, the Company recognized net revenues of \$2,039 and \$1,652, respectively, from a client that is a non-consolidating affiliate of the Company. \$1,095 of this amount is receivable as of March 31, 2016.

### *Cost of revenue from services*

The Company purchases certain services from its non-consolidating affiliates, mainly relating to training and recruitment, which are included in cost of revenue. For the three months ended March 31, 2015 and 2016, cost of revenue includes \$390 and \$498, respectively, attributable to the cost of services provided by the Company's non-consolidating affiliates.

**GENPACT LIMITED AND ITS SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**  
**(Unaudited)**  
**(In thousands, except per share data and share count)**

**23. Related party transactions (Continued)**

*Selling, general and administrative expenses*

The Company purchases certain services from its non-consolidating affiliates, mainly relating to training and recruitment, the costs of which are included in selling, general and administrative expenses. For the three months ended March 31, 2015 and 2016, selling, general and administrative expenses includes \$95 and \$67, respectively, attributable to the cost of services provided by the Company's non-consolidating affiliates.

During the three months ended March 31, 2015 and 2016, the Company engaged a significant shareholder to provide services to the Company at a cost of \$399 and \$15 respectively.

*Investment in equity affiliates*

During the three months ended March 31, 2016, the Company invested \$3,783 in its non-consolidating affiliates. As of December 31, 2015 and March 31, 2016, \$3,736 and \$3,736, respectively, in investments in equity affiliates was accrued but not paid and has been included in accrued expenses and other current liabilities in the Company's consolidated balance sheet.

As of December 31, 2015 and March 31, 2016, the Company's investments in its non-consolidating affiliates amounted to \$6,677 and \$8,315, respectively.

*Others*

During the three months ended March 31, 2016, the Company also entered into transactions with one of its non-consolidating affiliates for certain cost reimbursements amounting to \$329. As of December 31, 2015 and March 31, 2016, \$853 and \$329 is receivable, respectively.

**24. Commitments and contingencies**

*Capital commitments*

As of December 31, 2015 and March 31, 2016, the Company has committed to spend \$8,237 and \$7,337, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of these purchases.

*Bank guarantees*

The Company has outstanding bank guarantees amounting to \$11,748 and \$12,077 as of December 31, 2015 and March 31, 2016, respectively. Bank guarantees are generally provided to government agencies and excise and customs authorities for the purposes of maintaining bonded warehouses. These guarantees may be revoked by such government agencies if they suffer any losses or damages through the breach of any covenants contained in the agreements governing such guarantees.

*Other commitments*

The Company's business process delivery centers in India are 100% export oriented units or Software Technology Parks of India ("STPI") units under the STPI guidelines issued by the Government of India. These units are exempt from customs, central excise duties, and levies on imported and indigenous capital goods, stores, and spares. The Company has undertaken to pay custom duties, service taxes, levies, and liquidated damages payable, if any, in respect of imported and indigenous capital goods, stores, and spares consumed duty free, in the event that certain terms and conditions are not fulfilled.

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2015 and with the information under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2015. In addition to historical information, this discussion includes forward-looking statements and information that involves risks, uncertainties and assumptions, including but not limited to those listed below and under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015.

### Special Note Regarding Forward-Looking Statements

We have made statements in this Quarterly Report on Form 10-Q (the “Quarterly Report”) in, among other sections, Part I, Item 2—“Management’s Discussion and Analysis of Financial Condition and Results of Operations” that are forward-looking statements. In some cases, you can identify these statements by forward-looking terms such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “could,” “may,” “shall,” “will,” “would” and variations of such words and similar expressions, or the negative of such words or similar expressions. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, which in some cases may be based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks outlined in Part I, Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015.

These forward-looking statements include, but are not limited to, statements relating to:

- our ability to retain existing clients and contracts;
- our ability to win new clients and engagements;
- the expected value of the statements of work under our master service agreements;
- our beliefs about future trends in our market;
- political, economic or business conditions in countries where we have operations or where our clients operate;
- expected spending on business process outsourcing and information technology services by clients;
- foreign currency exchange rates;
- our ability to convert bookings to revenue;
- our rate of employee attrition;
- our effective tax rate; and
- competition in our industry.

Factors that may cause actual results to differ from expected results include, among others:

- our ability to grow our business and effectively manage growth and international operations while maintaining effective internal controls;
- our dependence on revenues derived from clients in the United States and Europe and clients that operate in certain industries, such as the financial services industry;
- our dependence on favorable tax legislation and tax policies that may be amended in a manner adverse to us or be unavailable to us in the future;
- our ability to successfully consummate or integrate strategic acquisitions;
- our ability to maintain pricing and asset utilization rates;
- our ability to hire and retain enough qualified employees to support our operations;
- increases in wages in locations in which we have operations;

## Table of Contents

- our relative dependence on the General Electric Company (GE) and our ability to maintain our relationships with divested GE businesses;
- financing terms, including, but not limited to, changes in the London Interbank Offered rate, or LIBOR;
- restrictions on visas for our employees traveling to North America and Europe;
- fluctuations in exchange rates between the U.S. dollar, the euro, U.K. pound sterling, Chinese renminbi, Hungarian forint, Japanese yen, Indian rupee, Australian dollar, Philippines peso, Guatemalan quetzal, Mexican peso, Polish zloty, Romanian leu, South African rand, Hong Kong dollar, Singapore dollar, Arab Emirates dirham, Brazilian real, Swiss franc, Swedish krona, Danish krone, Kenyan shilling, Czech koruna and Canadian dollar;
- our ability to retain senior management;
- the selling cycle for our client relationships;
- our ability to attract and retain clients and our ability to develop and maintain client relationships on attractive terms;
- legislation in the United States or elsewhere that adversely affects the performance of business process outsourcing and information technology services offshore;
- increasing competition in our industry;
- telecommunications or technology disruptions or breaches, or natural or other disasters;
- our ability to protect our intellectual property and the intellectual property of others;
- our ability to maintain the security and confidentiality of personal and other sensitive data of our clients, employees or others;
- deterioration in the global economic environment and its impact on our clients, including the bankruptcy of our clients;
- regulatory, legislative and judicial developments, including the withdrawal of governmental fiscal incentives;
- the international nature of our business;
- technological innovation;
- our ability to derive revenues from new service offerings; and
- unionization of any of our employees.

Although we believe the expectations reflected in any forward-looking statements are reasonable at the time they are made, we cannot guarantee future results, level of activity, performance or achievements. Achievement of future results is subject to risks, uncertainties, and potentially inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. We undertake no obligation to update any of these forward-looking statements after the date of this filing to conform our prior statements to actual results or revised expectations. You are advised, however, to consult any further disclosures we make on related subjects in our Forms 10-K, Forms 10-Q and Form 8-K reports to the SEC.



## Overview

Genpact stands for “generating business impact.” We are a global leader in digitally-powered business process management and services. We architect the Lean Digital<sup>SM</sup> enterprise through our patented Smart Enterprise Processes (SEPS<sup>SM</sup>) framework that reimagines our clients’ operating models end-to-end, including the middle and back offices. This creates Intelligent Operations<sup>SM</sup> that we help design, transform, and run. For two decades, first as a General Electric division and later as an independent company, we have been passionately serving our clients. Today, we generate impact for a few hundred strategic clients, including approximately one fifth of the Fortune Global 500, and have grown to over 70,000 people in 25 countries, with corporate offices in New York City.

In the quarter ended March 31, 2016, we had net revenues of \$609.7 million, of which \$502.3 million, or 82.4%, was from clients other than GE, which we refer to as Global Clients, with the remaining \$107.4 million, or 17.6%, coming from GE.

For the 12-month period ended March 31, 2016, the number of client relationships generating annual revenue over \$5 million increased to 105 from 94 as of March 31, 2015. This includes client relationships with more than \$15 million in annual revenue increasing to 34 from 30, and client relationships with more than \$25 million in annual revenue increasing to 18 from 17 over the same period.

Our registered office is located at Canon’s Court, 22 Victoria Street, Hamilton HM 12, Bermuda.

## Acquisitions

On January 8, 2016, we acquired 51% of the outstanding equity interest in Strategic Sourcing Excellence LLC (“SSE”), a Delaware limited liability company, for initial cash consideration of \$2,550, subject to adjustment for closing date working capital, transaction expenses and indebtedness. This acquisition strengthens our procurement consulting, transformation and strategic sourcing capabilities.

The equity purchase agreement provides for contingent earn-out consideration of up to \$20,000, payable based on future performance relative to the thresholds specified in the earn-out calculation. Up to \$9,800 of the total potential earn-out consideration, representing the selling equityholders’ 49% interest in SSE, is payable only if either the put or call option, each as described below, is exercised. Goodwill arising from the acquisition amounted to \$14.5 million, which has been allocated to our India reporting unit and is deductible for tax purposes.

The equity purchase agreement grants the Company a call option to purchase the remaining 49% equity interest in SSE, which option the Company has the right to exercise between January 1, 2018 and January 31, 2018. If the Company does not exercise its call option during such period, the selling equityholders have the right to exercise a put option between March 1, 2018 and April 30, 2018 to require the Company to purchase their 49% interest in SSE at a price ranging from \$2.5 million to \$3.0 million.

## Critical Accounting Policies and Estimates

For a description of our critical accounting policies, see Note 2—“Summary of significant accounting policies” under Part I, Item 1—“Financial Statements” above, Part II, Item 7—“Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates,” and Note 2—“Summary of significant accounting policies” under Part IV, Item 15—“Exhibits and Financial Statement Schedules” in our Annual Report on Form 10-K for the year ended December 31, 2015.

[Table of Contents](#)

**Results of Operations**

The following table sets forth certain data from our consolidated statements of income for the three months ended March 31, 2015 and 2016.

|                                                                                                             | <b>Three months ended March 31,</b> |                | <b>Percentage Change<br/>Increase/(Decrease)<br/>2016 vs. 2015</b> |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------|--------------------------------------------------------------------|
|                                                                                                             | <b>2015</b>                         | <b>2016</b>    |                                                                    |
|                                                                                                             | <b>(dollars in millions)</b>        |                |                                                                    |
| Net revenues—GE                                                                                             | \$ 113.6                            | \$ 107.4       | (5.5)%                                                             |
| Net revenues—Global Clients                                                                                 | 473.5                               | 502.3          | 6.1%                                                               |
| <b>Total net revenues</b>                                                                                   | <b>587.2</b>                        | <b>609.7</b>   | <b>3.8%</b>                                                        |
| Cost of revenue                                                                                             | 357.5                               | 372.8          | 4.3%                                                               |
| <b>Gross profit</b>                                                                                         | <b>229.7</b>                        | <b>236.9</b>   | <b>3.1%</b>                                                        |
| <b>Gross profit margin</b>                                                                                  | <b>39.1%</b>                        | <b>38.8%</b>   |                                                                    |
| Operating expenses                                                                                          |                                     |                |                                                                    |
| Selling, general and administrative expenses                                                                | 148.7                               | 160.1          | 7.7%                                                               |
| Amortization of acquired intangible assets                                                                  | 7.3                                 | 6.1            | (16.3)%                                                            |
| Other operating (income) expense, net                                                                       | (0.5)                               | (5.1)          | 995.5%                                                             |
| <b>Income from operations</b>                                                                               | <b>74.1</b>                         | <b>75.6</b>    | <b>2.1%</b>                                                        |
| <b>Income from operations as a percentage of total net revenues</b>                                         | <b>12.6%</b>                        | <b>12.4%</b>   |                                                                    |
| Foreign exchange gains (losses), net                                                                        | (7.5)                               | (1.0)          | (86.8)%                                                            |
| Interest income (expense), net                                                                              | (9.0)                               | (2.8)          | (68.6)%                                                            |
| Other income (expense), net                                                                                 | 0.5                                 | 0.9            | 91.7%                                                              |
| <b>Income before equity-method investment activity, net and income tax expense</b>                          | <b>57.9</b>                         | <b>72.7</b>    | <b>25.4%</b>                                                       |
| Gain (loss) on equity-method investment activity, net                                                       | (2.2)                               | (2.1)          | (3.5)%                                                             |
| <b>Income before income tax expense</b>                                                                     | <b>55.7</b>                         | <b>70.5</b>    | <b>26.6%</b>                                                       |
| Income tax expense                                                                                          | 11.1                                | 12.2           | 10.7%                                                              |
| <b>Net income</b>                                                                                           | <b>44.7</b>                         | <b>58.3</b>    | <b>30.5%</b>                                                       |
| Net loss (income) attributable to non-controlling interest                                                  | —                                   | 0.3            | 100.0%                                                             |
| <b>Net income attributable to Genpact Limited common shareholders</b>                                       | <b>\$ 44.7</b>                      | <b>\$ 58.6</b> | <b>31.2%</b>                                                       |
| <b>Net income attributable to Genpact Limited common shareholders as a percentage of total net revenues</b> | <b>7.6%</b>                         | <b>9.6%</b>    |                                                                    |

**Three Months Ended March 31, 2016 Compared to the Three Months Ended March 31, 2015**

*Net revenues.* Our net revenues were \$609.7 million in the first quarter of 2016, up \$22.6 million, or 3.8%, from \$587.2 million in the first quarter of 2015. The growth in net revenues was driven by an increase in business process outsourcing, or BPO, services delivered to our Global Clients, including the impact of revenues derived from large, transformational deals. Adjusted for foreign exchange, primarily the impact of the euro and Australian dollar against the U.S. dollar, our net revenues grew 6.2% compared to the first quarter of 2015. Our average headcount increased by 6.5% to approximately 70,300 in the first quarter of 2016 from approximately 66,000 in the first quarter of 2015.

|                                               | <u>Three months ended March 31,</u> |                 | <u>Percentage Change</u><br><u>Increase/(Decrease)</u><br><u>2016 vs. 2015</u> |
|-----------------------------------------------|-------------------------------------|-----------------|--------------------------------------------------------------------------------|
|                                               | <u>2015</u>                         | <u>2016</u>     |                                                                                |
|                                               | (dollars in millions)               |                 |                                                                                |
| <b>Global Clients:</b>                        |                                     |                 |                                                                                |
| BPO services                                  | \$ 372.4                            | \$ 406.3        | 9.1%                                                                           |
| IT services                                   | 101.1                               | 96.0            | (5.1)                                                                          |
| <b>Total net revenues from Global Clients</b> | <b>473.5</b>                        | <b>\$ 502.3</b> | <b>6.1%</b>                                                                    |
| <b>GE:</b>                                    |                                     |                 |                                                                                |
| BPO services                                  | 88.7                                | 82.8            | (6.6)%                                                                         |
| IT services                                   | 25.0                                | 24.6            | (1.5)                                                                          |
| <b>Total net revenues from GE</b>             | <b>\$ 113.6</b>                     | <b>\$ 107.4</b> | <b>(5.5)%</b>                                                                  |
| Total net revenues from BPO Services          | 461.1                               | 489.1           | 6.1%                                                                           |
| Total net revenues from IT Services           | 126.1                               | 120.6           | (4.4)%                                                                         |
| <b>Total net revenues</b>                     | <b>\$ 587.2</b>                     | <b>\$ 609.7</b> | <b>3.8%</b>                                                                    |

Net revenues from Global Clients were \$502.3 million in the first quarter of 2016, up \$28.8 million, or 6.1%, from \$473.5 million in the first quarter of 2015. This increase was primarily driven by growth in our targeted verticals, including consumer product goods, banking and financial services, insurance and high tech. As a percentage of total net revenues, net revenues from Global Clients increased from 80.7% in the first quarter of 2015 to 82.4% in the first quarter of 2016.

Net revenues from GE were \$107.4 million in the first quarter of 2016, down \$6.2 million, or 5.5%, from the first quarter of 2015. The decline in net revenues from GE was in line with expected decreases in services delivered to GE in the first quarter of 2016, largely due to phase-outs of work we do for GE Capital Corporate. Net revenues from GE declined as a percentage of our total net revenues from 19.3% in the first quarter of 2015 to 17.6% in the first quarter of 2016.

During the first quarter ended March 31, 2016, GE divested certain businesses that Genpact continues to serve. Historically we have reclassified revenues from these divested GE businesses as Global Client revenues in each fiscal quarter beginning on the date of divestiture. However, we will now reclassify such revenue as Global Client revenue only at the end of each fiscal year. We believe that this change will allow us to provide a more consistent view of the trends underlying our Global Client and GE businesses. Accordingly, Global Client revenues for the first quarter of 2016 do not include revenues from certain businesses that GE divested during the quarter, which revenues are included in total GE revenues. If we had reclassified the revenue from such GE-divested businesses during the first quarter, Global Client revenues for the quarter ended March 31, 2016 would have been \$513 million and GE revenues would have been \$96 million.

Net revenues from BPO services were \$489.1 million, up \$28.0 million, or 6.1%, from \$461.1 million in the first quarter of 2015. This increase was primarily attributable to an increase in services delivered to our Global Clients, particularly core industry vertical operations, consulting, finance and accounting and analytics services. Net revenues from IT services were \$120.6 million in the first quarter of 2016, down \$5.5 million, or 4.4%, from \$126.1 million in the first quarter of 2015 due to a decline in revenues from Global Clients in the healthcare and capital markets verticals.

Net revenues from BPO services as a percentage of total net revenues increased to 80.2% in the first quarter of 2016 from 78.5% in the first quarter of 2015 with a corresponding decline in the percentage of total net revenues attributable to IT services.

## Table of Contents

*Cost of revenue and gross margin.* The following table sets forth the components of our cost of revenue and our resulting gross profit:

|                               | <u>Three months ended March 31,</u> |                 | <u>As a percentage of total net revenues</u> |              |
|-------------------------------|-------------------------------------|-----------------|----------------------------------------------|--------------|
|                               | <u>2015</u>                         | <u>2016</u>     | <u>2015</u>                                  | <u>2016</u>  |
|                               | (dollars in millions)               |                 |                                              |              |
| Personnel expenses            | \$ 242.9                            | \$ 254.0        | 41.4%                                        | 41.7%        |
| Operational expenses          | 102.8                               | 107.5           | 17.5                                         | 17.6         |
| Depreciation and amortization | 11.7                                | 11.3            | 2.0                                          | 1.8          |
| <b>Cost of revenue</b>        | <b>\$ 357.5</b>                     | <b>\$ 372.8</b> | <b>60.9%</b>                                 | <b>61.2%</b> |
| <b>Gross margin</b>           | <b>39.1%</b>                        | <b>38.8%</b>    |                                              |              |

Cost of revenue was \$372.8 million, up \$15.4 million, or 4.3%, from the first quarter of 2015. Wage inflation, an increase in our operational headcount and related increases in travel expenses in the first quarter of 2016 compared to the first quarter of 2015 all contributed to the increase in cost of revenue. The increase in cost of revenue was partially offset by lower IT expenses and favorable foreign exchange, primarily the depreciation of the Indian rupee and U.K. pound sterling against the U.S. dollar. Foreign exchange fluctuations cause gains and losses on our foreign currency hedges and have a translation impact when we convert our non-U.S. dollar income statement items to the U.S. dollar, our reporting currency.

Our gross margin decreased marginally from 39.1% in the first quarter of 2015 to 38.8% in the first quarter of 2016 due to the factors described above.

*Personnel expenses.* Personnel expenses as a percentage of total net revenues increased from 41.4% in the first quarter of 2015 to 41.7% in the first quarter of 2016. Personnel expenses in the first quarter of 2016 were \$254.0 million, up \$11.1 million, or 4.6%, from \$242.9 million in the first quarter of 2015. Personnel expenses increased primarily due to wage inflation, higher stock-based compensation expense and an approximately 4,100-person, or 7.1%, increase in our operational headcount in the first quarter of 2016 compared to the first quarter of 2015. These increases were partially offset by favorable foreign exchange.

*Operational expenses.* Operational expenses as a percentage of total net revenues marginally increased from 17.5% in the first quarter of 2015 to 17.6% in first quarter of 2016. Operational expenses were \$107.5 million, up \$4.7 million, or 4.6%, from the first quarter of 2015. Operational expenses increased primarily due to increases in travel expenses in the first quarter of 2016 compared to the first quarter of 2015, partially offset by favorable foreign exchange and lower IT expenses.

*Depreciation and amortization expenses.* Depreciation and amortization expenses as a percentage of total net revenues decreased from 2.0% in the first quarter of 2015 to 1.8% in the first quarter of 2016. Depreciation and amortization expenses as a component of cost of revenue were \$11.3 million, down \$0.5 million, or 3.9%, from the first quarter of 2015. This marginal decrease was primarily due to an increase in fully depreciated assets since first quarter of 2015 and favorable foreign exchange, partially offset by the expansion of certain existing facilities in India and a new delivery center in the U.S.

*Selling, general and administrative expenses.* The following table sets forth the components of our selling, general and administrative, or SG&A, expenses:

|                                                     | <u>Three months ended March 31,</u> |                 | <u>As a percentage of total net revenues</u> |              |
|-----------------------------------------------------|-------------------------------------|-----------------|----------------------------------------------|--------------|
|                                                     | <u>2015</u>                         | <u>2016</u>     | <u>2015</u>                                  | <u>2016</u>  |
|                                                     | (dollars in millions)               |                 |                                              |              |
| Personnel expenses                                  | \$ 105.8                            | \$ 108.4        | 18.0%                                        | 17.8%        |
| Operational expenses                                | 40.6                                | 49.6            | 6.9                                          | 8.1          |
| Depreciation and amortization                       | 2.3                                 | 2.2             | 0.4                                          | 0.4          |
| <b>Selling, general and administrative expenses</b> | <b>\$ 148.7</b>                     | <b>\$ 160.1</b> | <b>25.3%</b>                                 | <b>26.3%</b> |

SG&A expenses as a percentage of total net revenues increased from 25.3% in the first quarter of 2015 to 26.3% in the first quarter of 2016. SG&A expenses were \$160.1 million, up \$11.4 million, or 7.7%, from the first quarter of 2015. Our sales and marketing expenses as a percentage of net revenues were approximately 7.3% in the first quarter of 2016, unchanged from the first quarter of 2015. SG&A expenses increased due to wage inflation, investments in domain expertise and digital and analytics capabilities and resources, higher fees for professional services, a reserve for doubtful receivables, and the timing of certain costs in the first quarter of 2016. This increase was partially offset by favorable foreign exchange, primarily the depreciation of the Indian rupee and U.K. pound sterling against the U.S. dollar in the first quarter of 2016 compared to the first quarter of 2015.

## [Table of Contents](#)

*Personnel expenses.* As a percentage of total net revenues, personnel expenses decreased marginally from 18.0% in the first quarter of 2015 to 17.8% in the first quarter of 2016. Personnel expenses as a component of SG&A expenses were \$108.4 million, up \$2.6 million, or 2.4%, from the first quarter of 2015. The increase is primarily due to wage inflation and investments in domain expertise and digital and analytics capabilities and resources in the first quarter of 2016 compared to the first quarter of 2015. This increase was partially offset by a 7.3% decrease in our sales-team personnel expenses and favorable foreign exchange.

*Operational expenses.* As a percentage of total net revenues, operational expenses increased from 6.9% in the first quarter of 2015 to 8.1% in the first quarter of 2016. Operational expenses as a component of SG&A expenses were \$49.6 million, up \$9.0 million, or 22.2%, from the first quarter of 2015. This increase is primarily due to higher fees for professional services, a reserve for doubtful receivables and the timing of certain non-recurring travel and related costs in the first quarter of 2016, partially offset by favorable foreign exchange in the first quarter of 2016 compared to the first quarter of 2015.

*Depreciation and amortization.* Depreciation and amortization expenses as a percentage of total net revenues were 0.4% in the first quarter of 2016, unchanged from the first quarter of 2015. Depreciation and amortization expenses as a component of SG&A expenses were \$2.2 million, compared to \$2.3 million in the first quarter of 2015. This marginal decrease was primarily due to an increase in fully depreciated assets since the first quarter of 2015, partially offset by the expansion of certain existing facilities in India and a new delivery center in the U.S.

*Amortization of acquired intangibles.* Non-cash charges on account of the amortization of acquired intangibles were \$6.1 million, down \$1.2 million, or 16.3%, from the first quarter of 2015. This decrease is primarily due to a \$1.0 million decline in the amortization expense relating to Pharmalink Consulting Limited and Pharmalink Consulting Inc., which we acquired in the second quarter of 2014 and refer to as our “regulatory affairs acquisition.”

*Other operating (income) expense, net.* The following table sets forth the components of other operating (income) expense, net:

|                                                                                                               | <u>Three months ended March 31,</u> |                 | <u>Percentage change<br/>Increase/(Decrease)<br/>2016 vs. 2015</u> |
|---------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------------|--------------------------------------------------------------------|
|                                                                                                               | <u>2015</u>                         | <u>2016</u>     |                                                                    |
|                                                                                                               | (dollars in millions)               |                 |                                                                    |
| Other operating (income) expense                                                                              | \$ (0.5)                            | \$ (0.5)        | 7.8%                                                               |
| Provision for impairment on intangible assets                                                                 | —                                   | 4.9             | 100.0                                                              |
| Change in fair value of earn-out consideration and deferred consideration (relating to business acquisitions) | —                                   | (9.5)           | 100.0                                                              |
| <b>Other operating (income) expense, net</b>                                                                  | <b>\$ (0.5)</b>                     | <b>\$ (5.1)</b> | <b>995.5%</b>                                                      |
| <b>Other operating (income) expense, net as a percentage of total net revenues</b>                            | <b>(0.1)%</b>                       | <b>(0.8)%</b>   |                                                                    |

Other operating income, net of expense, was \$5.1 million, compared to \$0.5 million in the first quarter of 2015, primarily due to a \$9.5 million gain in the first quarter of 2016 as a result of changes in the fair value of earn-out consideration payable in connection with certain acquisitions. No such gains were recorded in first quarter of 2015. This income was partially offset by a \$4.9 million non-recurring charge in the first quarter of 2016 relating to a software intangible asset, which charge we discuss in Note 10—“Goodwill and intangible assets” under Part I, Item 1—“Financial Statements” above.

*Income from operations.* As a result of the foregoing factors, income from operations as a percentage of total net revenues decreased from 12.6% in the first quarter of 2015 to 12.4% in the first quarter of 2016. Income from operations increased by \$1.6 million to \$75.6 million in the first quarter of 2016 from \$74.1 million in the first quarter of 2015.

*Foreign exchange gains (losses), net.* Foreign exchange gains (losses), net represents the impact of the re-measurement of our non-functional currency assets and liabilities and related foreign exchange contracts. We recorded a net foreign exchange loss of \$1.0 million in the first quarter of 2016, down from \$7.5 million in the first quarter of 2015. The loss in the first quarter of 2016 was primarily a result of the appreciation of the Philippine peso, Brazilian real, euro, and Japanese yen against the U.S. dollar, and the depreciation of the U.K. pound sterling against the U.S. dollar during the quarter. Our net foreign exchange loss in the first quarter of 2015 was primarily due to the depreciation of the euro against the U.S. dollar during that quarter. The hedging of our balance sheet components also contributed to a smaller loss in the first quarter of 2016 compared to the first quarter of 2015.

## Table of Contents

*Interest income (expense), net.* The following table sets forth the components of interest income (expense), net:

|                                                                             | Three months ended March 31, |                 | Percentage Change<br>Increase/(Decrease)<br>2016 vs. 2015 |
|-----------------------------------------------------------------------------|------------------------------|-----------------|-----------------------------------------------------------|
|                                                                             | 2015                         | 2016            |                                                           |
| Interest income                                                             | \$ 1.2                       | \$ 2.4          | 97.7%                                                     |
| Interest expense                                                            | (10.2)                       | (5.2)           | (49.1)                                                    |
| <b>Interest income (expense), net</b>                                       | <b>\$ (9.0)</b>              | <b>\$ (2.8)</b> | <b>(68.6)%</b>                                            |
| <b>Interest income (expense), net as a percentage of total net revenues</b> | <b>(1.5)%</b>                | <b>(0.5)%</b>   |                                                           |

Our net interest expense decreased by \$6.2 million compared to the first quarter of 2015, primarily due to (i) a decrease in interest expense as a result of a reduced interest rate on the term loan under our new credit facility, which we discuss in the section titled “Liquidity and Capital Resources—Financial Condition” below, (ii) \$1.3 million in debt issuance costs and interest expense on the two short-term loans we obtained and repaid in the first quarter of 2015 in the amounts of \$672.5 million and \$737.5 million, respectively, in connection with certain internal reorganization transactions, and (iii) lower drawdown on our revolving credit facility in the first quarter of 2016 compared to the first quarter of 2015. Our interest income increased due to higher account balances, including in jurisdictions in which we earn higher interest rates, during the first quarter of 2016 compared to the first quarter of 2015. The weighted average rate of interest on our debt decreased from 3.3% in the first quarter of 2015 to 1.9% in the first quarter of 2016.

*Other income (expense), net.* Our net other income was \$0.9 million in the first quarter of 2016, up \$0.4 million from \$0.5 million in the first quarter of 2015.

*Equity-method investment activity, net.* Equity-method investment activity, net in the first quarter of 2016 represents our \$2.1 million share of loss, compared to our \$2.2 million share of loss in the first quarter of 2015, from our non-consolidated affiliate, Markit Genpact KYC Services Limited, a U.K.-based joint venture with Markit Group Limited formed in 2014.

*Income tax expense.* Our income tax expense increased from \$11.1 million in the first quarter of 2015 to \$12.2 million in the first quarter of 2016, representing an effective tax rate, or ETR, of 17.3%, down from 19.9% in the first quarter of 2015. The increase in our tax expense is due to higher pre-tax profits in the first quarter of 2016 compared to the first quarter of 2015. The decrease in our effective tax rate is primarily due to certain discrete items, including the reversal of tax reserves for uncertain tax positions.

*Net income attributable to non-controlling interest.* Non-controlling interest primarily refers to the profit or loss associated with the non-controlling interest in the operations of SSE in the first quarter of 2016, which we discuss in Note 3—“Business acquisitions” under Part I, Item 1—“Financial Statements” above.

*Net income attributable to Genpact Limited common shareholders.* As a result of the foregoing factors, net income attributable to Genpact Limited common shareholders as a percentage of total net revenues was 9.6% in the first quarter of 2016, up from 7.6% in the first quarter of 2015. Net income attributable to Genpact Limited common shareholders increased by \$13.9 million from \$44.7 million in the first quarter of 2015 to \$58.6 million in the first quarter of 2016.

## Liquidity and Capital Resources

### Overview

Information about our financial position as of December 31, 2015 and March 31, 2016 is presented below:

|                                               | As of December 31,    | As of March 31, | Percentage Change<br>Increase/(Decrease)<br>2016 vs. 2015 |
|-----------------------------------------------|-----------------------|-----------------|-----------------------------------------------------------|
|                                               | 2015                  | 2016            |                                                           |
|                                               | (dollars in millions) |                 |                                                           |
| Cash and cash equivalents                     | \$ 450.9              | \$ 429.8        | (4.7)%                                                    |
| Short-term borrowings                         | 21.5                  | 81.5            | 279.1                                                     |
| Long-term debt due within one year            | 39.1                  | 39.1            | —                                                         |
| Long-term debt other than the current portion | 737.3                 | 727.5           | (1.3)                                                     |
| Genpact Limited total shareholders' equity    | \$ 1,304.4            | \$ 1,349.6      | 3.5%                                                      |

**Financial Condition**

We have historically financed our operations and our expansion, including acquisitions, with cash from operations and borrowing facilities.

Our cash and cash equivalents were \$429.8 million as of March 31, 2016, down from \$450.9 million as of December 31, 2015. Our cash and cash equivalents are comprised of (a) \$259.1 million in cash in current accounts across all operating locations to be used for working capital and immediate capital requirements and (b) \$170.7 million in deposits with banks to be used for medium-term planned expenditures and capital requirements.

As of March 31, 2016, \$417.7 million of the \$429.8 million in cash and cash equivalents was held by our foreign (non-Bermuda) subsidiaries. \$10.0 million of this cash is held by a foreign subsidiary for which we expect to incur a tax liability and have accordingly accrued a deferred tax liability on the repatriation of \$8.0 million of retained earnings. \$98.8 million of the cash and cash equivalents held by our foreign subsidiaries is held in jurisdictions where no tax is expected to be imposed upon repatriation.

Pursuant to our share repurchase program, during the three months ended March 31, 2016, we purchased 1,356,199 of our common shares at a weighted average price of \$24.35 per share for an aggregate cash amount of approximately \$33.0 million. See Part II, Item 2—"Purchase of Equity Securities by the Issuer and Affiliated Purchasers" below for additional information and related disclosures.

We expect that in the future our cash from operations, cash reserves and debt capacity will be sufficient to finance our operations, our growth and expansion plans, and additional share repurchases we expect to make under our share repurchase program. Our working capital needs are primarily to finance our payroll and other administrative and information technology expenses in advance of the receipt of accounts receivable. Our primary capital requirements include opening new delivery centers, expanding related operations to support our growth, and financing acquisitions.

Cash flows from operating, investing and financing activities, as reflected in our Consolidated Statements of Cash Flows, are summarized in the following table:

|                                                             | <u>Three months ended March 31,</u> |                  | <u>Percentage Change</u><br><u>Increase/(Decrease)</u><br><u>2016 vs. 2015</u> |
|-------------------------------------------------------------|-------------------------------------|------------------|--------------------------------------------------------------------------------|
|                                                             | <u>2015</u>                         | <u>2016</u>      |                                                                                |
|                                                             | (dollars in millions)               |                  |                                                                                |
| Net cash provided by (used for)                             |                                     |                  |                                                                                |
| Operating activities                                        | \$ 24.3                             | \$ (11.8)        | (148.5)%                                                                       |
| Investing activities                                        | (31.8)                              | (31.5)           | (1.0)                                                                          |
| Financing activities                                        | (15.8)                              | 22.6             | (243.1)%                                                                       |
| <b>Net increase (decrease) in cash and cash equivalents</b> | <b>\$ (23.3)</b>                    | <b>\$ (20.7)</b> | <b>(11.2)%</b>                                                                 |

*Cash flows from operating activities.* Net cash utilized for operating activities was \$11.8 million in the three months ended March 31, 2016, compared to net cash generated from operating activities of \$24.3 million in the three months ended March 31, 2015. This is primarily due to a \$44.6 million net change in our operating assets and liabilities in the three months ended March 31, 2016 compared to the three months ended March 31, 2015, mainly driven by (i) a \$10.1 million increase in net income tax payments due to higher pre-tax income, the payment of prior year tax amounts, and the timing of estimated tax payments, each in the first quarter of 2016, (ii) higher bonus payments in the first quarter of 2016, (iii) higher upfront investments in certain large deals in the first quarter of 2016, and (iv) an increase in investments in trade receivables in the first quarter of 2016 primarily due to the adverse impact of an increase in days sales outstanding from 81 as of March 31, 2015 to 89 as of March 31, 2016, partially offset by a reduction in revenue volume in the first quarter of 2016 compared to the first quarter of 2015.

*Cash flows from investing activities.* Our net cash used for investing activities was \$31.5 million in the three months ended March 31, 2016, down \$0.3 million from the three months ended March 31, 2015. This decrease was primarily due to the payment of \$11.7 million for our wealth management acquisition in the first quarter of 2015 compared to the payment in the three months ended March 31, 2016 of \$2.3 million for our acquisition of SSE. Additionally, we invested \$3.8 million in our non-consolidated affiliate, Markit Genpact KYC Services Limited, in the three months ended March 31, 2016, down from \$6.7 million in the three months ended March 31, 2015. This decrease in net cash used for investing activities was partially offset by higher payments for purchases of property, plant and equipment (net of sales proceeds) of \$25.4 million in the three months ended March 31, 2016 compared to \$13.4 million in the three months ended March 31, 2015.

*Cash flows from financing activities.* Our net cash generated from financing activities was \$22.6 million in the three months ended March 31, 2016, compared to net cash used for financing activities of \$15.8 million in the three months ended March 31, 2015.



## [Table of Contents](#)

In the first quarter of 2016, we repaid \$10.0 million of the term loan under our new credit facility, compared to repayments of \$1.7 million in the first quarter of 2015. In the first quarter of 2016, we drew down \$60.0 million of our revolving credit facility to meet short-term internal funding requirements, which amount we expect to repay during the second quarter of 2016. In the first quarter of 2015, we obtained two short-term loans in the amounts of \$672.5 million and \$737.5 million, respectively, to finance certain internal reorganization transactions. These loans were fully repaid on January 30, 2015 and March 26, 2015, respectively. We paid debt issuance costs of \$1.0 million in connection with such loans. Additionally, proceeds from the issuance of common shares under stock-based compensation plans (net of payments) were \$4.0 million higher in the three months ended March 31, 2016 than in the three months ended March 31, 2015. Additionally, there was an excess tax benefit of \$2.2 million related to stock-based compensation in the first quarter of 2016. No such benefit was recorded in the first quarter of 2015. The impact of the foregoing items on cash flows was offset by higher share repurchase payments of \$33.0 million in the three months ended March 31, 2016 compared to \$13.3 million in the three months ended March 31, 2015.

### **Financing Arrangements (Credit Facility)**

In June 2015, we refinanced our 2012 facility through a new credit facility comprised of a term loan of \$800 million and a revolving credit facility of \$350 million. As of December 31, 2015 and March 31, 2016, our outstanding term loan debt, net of debt amortization expense of \$3.5 million and \$3.3 million, respectively, was \$776.5 million and \$766.7 million, respectively. We also have fund-based and non-fund based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2015 and March 31, 2016, the limits available under such facilities were \$15.8 million and \$15.5 million, respectively, of which \$10.3 million and \$10.6 million was utilized, constituting non-funded drawdown. For details on our financing arrangements, refer to notes 11 and 12 to our consolidated financial statements.

### **Off-Balance Sheet Arrangements**

Our off-balance sheet arrangements consist of foreign exchange contracts and certain operating leases. For additional information, see Part I, Item 1A—Risk Factors—“Currency exchange rate fluctuations in various currencies in which we do business, especially the Indian rupee, the U.S. dollar and the euro, could have a material adverse effect on our business, results of operations and financial condition” in our Annual Report on Form 10-K for the year ended December 31, 2015, the section titled “Contractual Obligations” below, and Note 7 in Part I, Item 1—“Financial Statements” above.

### **Contractual Obligations**

The following table sets forth our total future contractual obligations as of March 31, 2016:

|                                      | Total                 | Less than 1 year | 1-3 years       | 3-5 years       | After 5 years  |
|--------------------------------------|-----------------------|------------------|-----------------|-----------------|----------------|
|                                      | (dollars in millions) |                  |                 |                 |                |
| Long-term debt                       | \$ 829.9              | \$ 55.4          | \$ 108.4        | \$ 666.1        | \$ —           |
| - Principal payments                 | 766.6                 | 39.1             | 78.4            | 649.1           | —              |
| - Interest payments*                 | 63.3                  | 16.3             | 30.0            | 17.0            | —              |
| Short-term borrowings                | 81.9                  | 81.9             | —               | —               | —              |
| - Principal payments                 | 81.5                  | 81.5             | —               | —               | —              |
| - Interest payments**                | 0.4                   | 0.4              | —               | —               | —              |
| Capital leases                       | 4.2                   | 1.7              | 2.0             | 0.5             | —              |
| - Principal payments                 | 3.4                   | 1.3              | 1.7             | 0.4             | —              |
| - Interest payments                  | 0.8                   | 0.4              | 0.3             | 0.1             | —              |
| Operating leases                     | 141.1                 | 27.9             | 48.2            | 31.5            | 33.5           |
| Purchase obligations                 | 35.3                  | 26.2             | 8.2             | 0.9             | —              |
| Capital commitments net of advances  | 7.3                   | 7.3              | —               | —               | —              |
| Earn-out consideration               | 23.8                  | 5.0              | 12.2            | 6.6             | —              |
| - Reporting Date Fair Value          | 20.9                  | 4.7              | 10.4            | 5.8             | —              |
| - Interest                           | 2.9                   | 0.3              | 1.8             | 0.8             | —              |
| Other liabilities                    | 73.3                  | 41.2             | 20.2            | 11.9            | —              |
| <b>Total contractual obligations</b> | <b>\$1,196.8</b>      | <b>\$ 246.6</b>  | <b>\$ 199.2</b> | <b>\$ 717.5</b> | <b>\$ 33.5</b> |

\* Our interest payments on long-term debt are calculated based on our current debt rating at a rate equal to LIBOR plus a margin of 1.50% per annum as of March 31, 2016. Amounts shown exclude the impact of interest rate swaps.



## [Table of Contents](#)

\*\* Our interest payments on short-term debt are calculated based on our current debt rating at a rate equal to LIBOR plus a margin of 1.50% per annum as of March 31, 2016 and our expectation for the repayment of such debt.

### **Recent Accounting Pronouncements**

#### *Recently adopted accounting pronouncements*

For a description of recently adopted accounting pronouncements, see Note 2—“Recently adopted accounting pronouncements” under Item 1—“Financial Statements” above and Part II, Item 7—“Management’s Discussion and Analysis of Financial Condition and Results of Operations”—“Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2015.

#### *Recently issued accounting pronouncements*

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which will replace most existing revenue recognition guidance in U.S. GAAP. The core principle of the ASU is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. The ASU requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. In March 2016, the FASB issued ASU No. 2016-08, “Principal versus Agent Considerations (Reporting Gross versus Net).” The ASU amends the principal versus agent guidance in ASU 2014-09, “Revenue from Contracts with Customers” and clarifies that the analysis must focus on whether the entity has control of the good or services before they are transferred to the customer. In April 2016, the FASB issued ASU No. 2016-10, “Identifying performance obligations and licensing.” The ASU proposes certain amendments to the methods for identifying performance obligations and provides licensing implementation guidance. These ASUs will be effective for us beginning January 1, 2018, including interim periods in our fiscal year 2018, and allows for both retrospective and prospective adoption. We are in the process of determining the method of adoption and assessing the impact of this ASU on our consolidated results of operations, cash flows, financial position and disclosures.

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall: Recognition and Measurement of Financial Assets and Financial Liabilities,” which primarily affects accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The ASU will be effective for us beginning January 1, 2018, including interim periods in our fiscal year 2018. Early adoption is permitted. We are in the process of determining the method of adoption and assessing the impact of this ASU on our consolidated results of operations, cash flows, financial position and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. The ASU will be effective for us beginning January 1, 2019, including interim periods in our fiscal year 2019. Early adoption is permitted. We are in the process of determining the method of adoption and assessing the impact of this ASU on our consolidated results of operations, cash flows, financial position and disclosures.

In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting.” The ASU changes several aspects of accounting for share-based payment award transactions, including (i) accounting and cash flow classification for excess tax benefits and deficiencies, (ii) forfeitures, and (iii) tax withholding requirements and cash flow classification. The ASU will be effective for us beginning January 1, 2017, including interim periods in our fiscal year 2017. Early adoption is permitted. We are in the process of determining the method of adoption and assessing the impact of this ASU on our consolidated results of operations, cash flows, financial position and disclosures.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to interest rate risk arising from changes in interest rates on the floating rate indebtedness under our term loan. Borrowings under our term loan bear interest at floating rates based on LIBOR, but in no event less than the floor rate of 0.0% plus an applicable margin. Accordingly, fluctuations in market interest rates may increase or decrease our interest expense which will, in turn, increase or decrease our net income and cash flow.

We manage a portion of our interest rate risk related to floating rate indebtedness by entering into interest rate swaps under which we receive floating rate payments based on the greater of LIBOR and the floor rate under our term loan and make payments based on a fixed rate. As of March 31, 2016, we were party to interest rate swaps covering a total notional amount of \$200 million. Under these swap agreements, LIBOR is fixed at 1.20% through June 2020.

## [Table of Contents](#)

For a discussion of our market risk associated with foreign currency risk, interest rate risk and credit risk, see Part II, item 7A—“Quantitative and Qualitative Disclosures about Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2015.

### **Item 4. Controls and Procedures**

#### ***Evaluation of Disclosure Controls and Procedures***

Disclosure controls and procedures are the Company’s controls and other procedures which are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 (“Exchange Act”) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer along with the Company’s Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to the Exchange Act Rule 13a-15(b). Based upon that evaluation, the Company’s Chief Executive Officer along with the Company’s Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective in timely alerting them to material information relating to the Company (including its consolidated subsidiaries) required to be included in the Company’s periodic SEC filings.

#### ***Changes in Internal Control over Financial Reporting***

There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarterly period ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

In making its assessment of the changes in internal controls over financial reporting during the quarterly period ended March 31, 2016, management excluded an evaluation of the internal controls over financial reporting in respect of any acquisition made in the three months ended March 31, 2016. See Note 3 to the Unaudited Consolidated Financial Statements for a discussion of acquisitions consummated during such period.

## **PART II**

### **Item 1. Legal Proceedings**

There are no legal proceedings pending against us that we believe are likely to have a material adverse effect on our business, results of operations and financial condition.

### **Item 1A. Risk Factors**

We have disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 the risk factors that materially affect our business, financial condition or results of operations. You should carefully consider the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015 and the other information that appears elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us also may materially adversely affect our business, financial condition and/or results of operations.

### **Item 2. Unregistered Sale of Equity Securities and Use of Proceeds**

#### ***Unregistered Sales of Equity Securities***

None.

#### ***Use of Proceeds***

None.

#### ***Purchase of Equity Securities by the Issuer and Affiliated Purchasers***

In February 2015, our board of directors authorized a plan to repurchase up to \$250.0 million in value of our common shares. During the three months ended March 31, 2016, we completed \$250.0 million in share purchases under this program, and in February 2016 our board of directors approved an additional \$250 million share repurchase program, bringing the total authorization under our existing program to \$500 million since February 2015. Our share repurchase plan does not obligate us to acquire any specific number of shares and does not specify an expiration date. All shares repurchased under the plan will be cancelled.

## [Table of Contents](#)

Share repurchase activity during the three months ended March 31, 2016 was as follows:

| Period                         | Total Number of Shares Purchased | Average Price Paid per Share (\$) | Total Number of Shares Purchased as Part of Publicly Announced Plan or Program | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan or Program (\$) |
|--------------------------------|----------------------------------|-----------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| January 1 – January 31, 2016   | 956,048                          | 23.92                             | 956,048                                                                        | 216,495                                                                                     |
| February 1 – February 29, 2016 | 381,051                          | 25.33                             | 381,051                                                                        | 240,566,226                                                                                 |
| March 1 – March 31, 2016       | 19,100                           | 26.17                             | 19,100                                                                         | 240,066,379                                                                                 |

### **Item 3. Defaults Upon Senior Securities**

None.

### **Item 5. Other Information**

None.

### **Item 6. Exhibits**

|         |                                                                                                                                                                                                                             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1     | Memorandum of Association of the Registrant (incorporated by reference to Exhibit 3.1 to Amendment No. 2 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on July 16, 2007). |
| 3.3     | Bye-laws of the Registrant (incorporated by reference to Exhibit 3.3 to Amendment No. 4 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on August 1, 2007).                 |
| 31.1    | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*                         |
| 31.2    | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*                         |
| 32.1    | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*                                                                     |
| 32.2    | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*                                                                     |
| 101.INS | XBRL Instance Document (1)                                                                                                                                                                                                  |
| 101.SCH | XBRL Taxonomy Extension Schema Document (1)                                                                                                                                                                                 |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document (1)                                                                                                                                                                   |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document (1)                                                                                                                                                                    |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document (1)                                                                                                                                                                         |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document (1)                                                                                                                                                                  |

\* Filed with this Quarterly Report on Form 10-Q.

(1) Filed as Exhibit 101 to this report are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2015 and March 31, 2016, (ii) Consolidated Statements of Income for the three months ended March 31, 2015 and March 31, 2016, (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2015 and March 31, 2016, (iv) Consolidated Statements of Equity for the three months ended March 31, 2015, Consolidated Statements of Equity and Redeemable Non-controlling Interest for the three months ended March 31, 2016, (v) Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and March 31, 2016, and (vi) Notes to the Consolidated Financial Statements.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 9, 2016

GENPACT LIMITED

By: /s/ N.V. TYAGARAJAN

**N.V. Tyagarajan**  
**Chief Executive Officer**

By: /s/ EDWARD J. FITZPATRICK

**Edward J. Fitzpatrick**  
**Chief Financial Officer**

**EXHIBIT INDEX**

| <b><u>Exhibit Number</u></b> | <b><u>Description</u></b>                                                                                                                                                                                                   |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1                          | Memorandum of Association of the Registrant (incorporated by reference to Exhibit 3.1 to Amendment No. 2 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on July 16, 2007). |
| 3.3                          | Bye-laws of the Registrant (incorporated by reference to Exhibit 3.3 to Amendment No. 4 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on August 1, 2007).                 |
| 31.1                         | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*                         |
| 31.2                         | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*                         |
| 32.1                         | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*                                                                     |
| 32.2                         | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*                                                                     |
| 101.INS                      | XBRL Instance Document (1)                                                                                                                                                                                                  |
| 101.SCH                      | XBRL Taxonomy Extension Schema Document (1)                                                                                                                                                                                 |
| 101.CAL                      | XBRL Taxonomy Extension Calculation Linkbase Document (1)                                                                                                                                                                   |
| 101.DEF                      | XBRL Taxonomy Extension Definition Linkbase Document (1)                                                                                                                                                                    |
| 101.LAB                      | XBRL Taxonomy Extension Label Linkbase Document (1)                                                                                                                                                                         |
| 101.PRE                      | XBRL Taxonomy Extension Presentation Linkbase Document (1)                                                                                                                                                                  |

\* Filed with this Quarterly Report on Form 10-Q.

(1) Filed as Exhibit 101 to this report are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2015 and March 31, 2016, (ii) Consolidated Statements of Income for the three months ended March 31, 2015 and March 31, 2016, (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2015 and March 31, 2016, (iv) Consolidated Statements of Equity for the three months ended March 31, 2015, Consolidated Statements of Equity and Redeemable Non-controlling Interest for the three months ended March 31, 2016, (v) Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and March 31, 2016, and (vi) Notes to the Consolidated Financial Statements.

## CHIEF EXECUTIVE OFFICER CERTIFICATION

I, N.V. Tyagarajan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Genpact Limited for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 9, 2016

/s/ N.V. TYAGARAJAN

N.V. Tyagarajan

Chief Executive Officer

## CHIEF FINANCIAL OFFICER CERTIFICATION

I, Edward J. Fitzpatrick, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Genpact Limited for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 9, 2016

/s/ EDWARD J. FITZPATRICK

---

Edward J. Fitzpatrick  
Chief Financial Officer

**Certification of the Chief Executive Officer**  
**Pursuant to 18 U.S.C. Section 1350,**  
**As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Genpact Limited (the "Company") on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, N.V. Tyagarajan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2016

/s/ N.V. TYAGARAJAN

\_\_\_\_\_  
N.V. Tyagarajan

*Chief Executive Officer*



**Certification of the Chief Financial Officer**  
**Pursuant to 18 U.S.C. Section 1350,**  
**As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Genpact Limited (the "Company") on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Fitzpatrick, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2016

/s/ EDWARD J. FITZPATRICK

---

Edward J. Fitzpatrick  
*Chief Financial Officer*  
*Genpact Limited*